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2 ABBREVIATIONS
ABC  antibody-binding capacity
ACCP  the American College of Chest Physicians
APP  acute phase protein
AUC  area under curve
BSI  bloodstream infection 
CAI   community-acquired infection
CAP  community-acquired pneumonia
CD  cluster of diff erentiation
CI  confi dence interval
COPD  chronic obstructive pulmonary disease
CR  complement receptor
CRP  C-reactive protein
ED  emergency department
ELISA  enzyme-linked immunosorbent assay
FACS  fl uorescence-activated cell sorter
FITC  fl uorescein isothiocyanate
GPI  glycosylphosphatidylinositol
HLA  human leukocyte antigen
HUCH  Helsinki University Central Hospital
HUSLAB the laboratories of the hospital district of Helsinki and 
  Uusimaa
IBD  infl ammatory bowel disease
ICAM  intercellular adhesion molecule
IFN  interferon
IL  interleukin
IQR  interquartile ratio
LFA  leukocyte functional antigen
LPS  lipopolysaccharide
LBP  LPS-binding protein
LR+  positive likelihood ratio
LRTi  lower respiratory tract infection
MAP  mean arterial pressure
MEDS  Mortality in Emergency Department score
MHC  major histocompatibility complex
MI  myocardial infarction
MO  monocyte
N/A  not available
NADPH nicotinamide adenine dinucleotide phosphate
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NFκB  nuclear factor kappa B
NPV  negative predictive value
PAF  platelet-activating factor
PAMP  pathogen-associated molecular pattern
PCT  procalcitonin
PMN  polymorphonuclear leukocyte
PPV  positive predictive value
PRR  pattern-recognition receptor
QSC  Quantum Simply Cellular® 
SCCM  the Society of Critical Care Medicine
mCD14  membrane CD14
sCD14  soluble CD14
sIL-2R  soluble interleukin-2 receptor
SIRS  systemic infl ammatory response syndrome
TLR  Toll-like receptor
TNF  tumour necrosis factor
UTI  urinary tract infection
WBC  white blood cell 
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3 ABSTRACT IN FINNISH
Sairaalan päivystysvastaanotolle lähetetyllä äkillisesti sairaalla potilaalla 
sairauden yleinen syy on infektio eli elimistöön joutuneen mikrobin 
aiheuttama oireinen sairaus. Infektio voi aiheuttaa elimistössä paikallisen 
tulehduspesäkkeen eli fokuksen tai se voi synnyttää yleistyneen 
tulehdusvasteen, jossa verenkiertoon vapautuu suuria määriä tulehduksen 
välittäjäaineita. Infektion aiheuttamaa yleistynyttä tulehdusvastetta 
kutsutaan sepsikseksi. Sepsiksen vastine puhekielessä on verenmyrkytys, 
jolla perinteisesti on tarkoitettu mikrobien esiintymistä veressä ja veriviljelyn 
positiivisuutta. Äkillisesti kotona sairastuneella potilaalla kyseessä on ns. 
avohoito- eli kotisyntyinen infektio. Useimmiten infektio ja fokus pystytään 
toteamaan sairaalaan tullessa ja antibioottilääkehoito parantaa taudin. 
Toisilla potilailla äkillisen sairauden syy ei selviä ensimmäisen vuorokauden 
aikana eikä piilevän infektion mahdollisuutta pystytä poissulkemaan. 
Erityisesti sepsiksen varmistuminen saattaa viivästyä, jos infektiofokusta 
ei tulovaiheessa löydy ja veriviljelyn tulosta joudutaan odottamaan useita 
päiviä. Infektiopotilaiden yleistila voi huonontua nopeasti ja johtaa 
verenkierron lamaantumiseen eli sokkiin, jopa kuolemaan. Näiden potilaiden 
tunnistaminen varhaisvaiheessa esimerkiksi verestä mitattavilla tulehduksen 
merkkiaineilla auttaisi tehostamaan hoitotoimenpiteitä sekä kohdentamaan 
uusia, kalliita tulehdusvasteeseen vaikuttavia lääkehoitoja.  
Tämän väitöskirjan tarkoituksena oli selvittää verestä mitattavien, 
pääasiassa synnynnäiseen immuniteettiin (engl. innate immunity) 
kuuluvien tulehduksen merkkiaineiden käyttökelpoisuutta sairaalan 
päivystysvastaanotolle tulevilla potilailla. Erityisesti tutkittiin tulehduksen 
merkkiaineiden käyttökelpoisuutta positiivisen veriviljelyn ennustamisessa 
ja piilevän kotisyntyisen infektion toteamisessa. Lisäksi selvitettiin, onko 
merkkiaineista taudin alkuvaiheessa hyötyä kotisyntyistä infektioita 
sairastavien potilaiden kuolleisuuden ennustamisessa. 
Meilahden sairaalan eettinen toimikunta hyväksyi tutkimussuunnitelman. 
Tutkimusprojektia varten tutkittiin 1092 äkillisesti sairasta potilasta Helsingin 
yliopistollisen sairaalan Meilahden sisätautien päivystyspoliklinikalla 
vuosina 1997–98. Päivystävän lääkärin epäiltyä sepsistä potilaista otettiin 
päivystyspoliklinikalla veriviljelynäytteet, ja samalla otettiin rinnakkainen 
verinäyte tutkimusta varten. Näytteistä mitattiin vuorokauden sisällä 
virtaussytometrilla solusitoisia tulehduksen merkkiaineita, minkä jälkeen 
loppu plasmanäyte pakastettiin myöhempiä liukoisten merkkiaineiden 
mittauksia varten. Lopulliseen analyysiin otettiin 531 potilasta, joilla 
varmentui kotisyntyinen infektio tai oli vahva epäily siitä.
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Veriviljelyn positiivisen tuloksen ennustaminen tulehduksen 
merkkiaineilla mukaan lukien C-reaktiivinen proteiini (CRP), prokalsitoniini 
(PCT), interleukiini (IL)-6, IL-8 ja liukoinen IL-2 reseptori (sIL-2R) ei 
onnistunut paremmin kuin pelkillä kliinisillä mittareilla. Kliinisinä 
ennustekijöinä käytettiin kuumetta, infektiofokusta, verenpainetta (MAP) 
ja pulssia. 
Piilevän kotisyntyisen infektion diagnostiikkaa voitiin parantaa 
tulehduksen merkkiaineilla. Parhaita merkkiaineita olivat PCT ja IL-6 
mitattuna positiivisella uskottavuusosamäärällä (positive likelihood 
ratio). Mikään yksittäinen merkkiaine ei kuitenkaan löytänyt kaikkia 
potilaita, joilla oli piilevä infektio. Sen sijaan yhdistelmä sisältäen nopeasti 
reagoivan merkkiaineen (CD11b), hitaammin nousevan merkkiaineen 
(CRP) ja kudoslähtöisen merkkiaineen (IL-8) kykeni tunnistamaan kaikki 
infektiopotilaat. Tätä yhdistelmää käytettiin myös niiden potilaiden 
tarkasteluun, joilla infektiota ei löytynyt, mutta sitä ei voitu varmuudella 
poissulkeakaan. Näistä potilaista 86,5%:lla ainakin jokin yhdistelmän 
merkkiaineista ylitti raja-arvon vahvistaen infektion mahdollisuutta.
Kotisyntyistä infektiota sairastavien potilaiden 28-päivän kuolleisuus 
oli matala, 3,4%. Monimuuttuja-analyysissä korkea ikä ja monosyyttien 
solusitoisen lipopolysakkaridireseptorin eli CD14-molekyylin alhainen 
määrä ennustivat kuolleisuutta taudin alkuvaiheessa. CD14-reseptoria 
esiintyy myös liukoisessa muodossa (sCD14), mutta korkea sCD14 pitoisuus 
ei ollut kuoleman suhteen ennusteellinen. Korkeampi kuolleisuus todettiin 
potilailla, joilla oli samanaikaisesti matala solusitoisen CD14-reseptorin 
määrä ja korkea sCD14-pitoisuus.
Tulehduksen merkkiaineet parantavat piilevien kotisyntyisten infektioiden 
diagnostiikkaa taudin alkuvaiheessa, mutta yksittäisiä potilaita tutkittaessa 
täytyy käyttää useiden merkkiaineiden yhdistelmää mieluummin kuin 
yksittäistä merkkiainetta. Sairaalaan tulovaiheessa matala solusitoisen 
lipopolysakkaridireseptorin (mCD14) määrä ennustaa kuolemaa kotisyntyistä 
infektiota sairastavalla potilaalla. 
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4 ABSTRACT
Sepsis is associated with a systemic infl ammatory response. It is 
characterised by an early proinfl ammatory response and followed by a 
state of immunosuppression. In order to improve the outcome of patients 
with infection and sepsis, novel therapies that infl uence the systemic 
infl ammatory response are being developed and utilised. Th us, an accurate 
and early diagnosis of infection and evaluation of immune state are crucial. 
In this thesis, various markers of systemic infl ammation were studied with 
respect to enhancing the diagnostics of infection and of predicting outcome 
in patients with suspected community-acquired infection. 
A total of 1092 acutely ill patients admitted to a university hospital medical 
emergency department were evaluated, and 531 patients with a suspicion 
of community-acquired infection were included for the analysis. Markers 
of systemic infl ammation were determined from a blood sample obtained 
simultaneously with a blood culture sample on admission to hospital. Levels 
of phagocyte CD11b/CD18 and CD14 expression were measured by whole 
blood fl ow cytometry. Concentrations of soluble CD14, interleukin (IL)-8, 
and soluble IL-2 receptor α (sIL-2Rα) were determined by ELISA, those 
of sIL-2R, IL-6, and IL-8 by a chemiluminescent immunoassay, that of 
procalcitonin by immunoluminometric assay, and that of C-reactive protein 
by immunoturbidimetric assay. Clinical data were collected retrospectively 
from the medical records. 
No marker of systemic infl ammation, neither CRP, PCT, IL-6, IL-8, nor 
sIL-2R predicted bacteraemia better than did the clinical signs of infection, 
i.e., the presence of infectious focus or fever or both.  IL-6 and PCT had 
the highest positive likelihood ratios to identify patients with hidden 
community-acquired infection. However, the use of a single marker failed 
to detect all patients with infection. A combination of markers including 
a fast-responding reactant (CD11b expression), a later-peaking reactant 
(CRP), and a reactant originating from infl amed tissues (IL-8) detected 
all patients with infection. Th e majority of patients (86.5%) with possible 
but not verifi ed infection showed levels exceeding at least one cut-off  limit 
of combination, supporting the view that infection was the cause of their 
acute illness.
Th e 28-day mortality of patients with community-acquired infection 
was low (3.4%). On admission to hospital, the low expression of cell-
associated lipopolysaccharide receptor CD14 (mCD14) was predictive for 
28-day mortality. In the patients with severe forms of community-acquired 
infection, namely pneumonia and sepsis, high levels of soluble CD14 alone 
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did not predict mortality, but a high sCD14 level measured simultaneously 
with a low mCD14 raised the possibility of poor  prognosis.
In conclusion, to further enhance the diagnostics of hidden community-
acquired infection, a combination of infl ammatory markers is useful. Th e 
28-day mortality is associated with low levels of mCD14 expression at an 
early phase of the disease.
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5 INTRODUCTION
Community-acquired infection (CAI) can aff ect everyone. It is contracted 
during normal activities of daily life, and only the most serious forms 
require evaluation and subsequent treatment at a tertiary care hospital 
emergency department (ED). Infectious focus is usually evident on referral 
to hospital. Classical signs of infl ammation, namely rubor (erythema), 
tumour (edema), calor (heat), dolor (pain), and functio laesa (disturbed 
function) aid in clinical diagnosis of infection. Th e innate immune response 
aroused at an early stage of infection is the essential part of the host defence 
against invading organisms. Systemic infl ammation is accompanied by 
a large number of changes in humoral and cell-associated functions of 
innate immunity. Although the main reason for these changes is the defence 
and adaptation of the host, an exaggerated or inappropriately suppressed 
systemic infl ammatory response may lead to severe disturbance of organs 
or even death.  Th e critical question is how to measure the severity of the 
innate immune response triggered by community-acquired infection and 
how to identify the patients at risk for poor outcome. An ideal marker of 
sepsis should allow an early diagnosis, help to diff erentiate infectious from 
non-infectious causes of systemic infl ammation, and be informative as to 
the course and prognosis of the condition in question. Th e search for a 
single “magic” marker with high sensitivity and specifi city for infection and 
with the ability to accurately predict outcome has encountered numerous 
setbacks [Cooney and Yumet 2002, Takala et al. 2002b, Beale 2007, Tang 
et al. 2007].  
Attending clinicians in an ED oft en encounter an acutely ill patient with 
fever. Infection is one of the most common disorders underlying fever, and 
its detection and diagnostics have greatly improved. Th e diagnosis of sepsis, a 
serious consequence of the body’s failed control over a local infectious focus 
and the microbes involved, is traditionally based on blood cultures. Th e 
father of microbiology, Louis Pasteur, showed for the fi rst time that bacteria 
were present in the blood from patients with puerperal sepsis. Robert Koch 
and his assistant Julius Richard Petri laid the foundation for the techniques of 
culturing bacteria. Koch underlined the interconnection between laboratory 
results and clinical illness. Still, despite serious acute septic-like illness, blood 
cultures oft en remain negative for many reasons, and the patient’s poor 
outcome results not from spreading of the microbe(s) as such but mostly 
from an exaggerated or inappropriately suppressed systemic infl ammatory 
response. For this reason, the focus of sepsis research has been extended to 
the systemic infl ammatory response. 
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Th is thesis comprises a uniquely large series of acutely ill patients with 
a suspicion of CAI in a tertiary care hospital ED. Th e aim of these studies 
was, upon admission to an ED, to enhance early diagnostics of CAI, and to 
predict outcome among patients with CAI. 
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6 REVIEW OF THE LITERATURE
6.1 INFLAMMATION
Infl ammation is the host’s response to tissue injury produced by mechanical, 
chemical, or microbial stimuli. Any immune response involves, fi rstly, the 
recognition of the pathogen or other foreign material, and secondly, its 
elimination [Roitt et al. 2002]. Immune responses are classically divided 
into two types based on the speed and specifi city of the reaction, namely 
innate and adaptive responses [Dempsey et al. 2003]. Innate immunity 
provides an immediate host defence (neutrophils, monocytes, macrophages, 
complement, cytokines, and acute phase proteins). It is rapid and occurs 
to the same extent independently to frequent encounters with the same 
infectious agent. Th e adaptive response consists, among other things, of 
antigen-specifi c reactions through T-lymphocyte immunity involving 
CD4-positive T-helper (TH cells) and CD8-positive cytotoxic T cells, and 
of antibody formation by B lymphocytes. Th e adaptive response is precise 
but takes several days or weeks to develop, and it has a memory [Parkin 
and Cohen 2001]. 
Th e sensing of invading micro-organisms by innate immune cells is 
considered to involve pattern recognition. Microbial pathogens are 
characterised by specifi c arrangements of key molecules called pathogen-
associated molecular patterns (PAMPs). Because PAMPs are structures vital 
for the pathogen’s function, they have altered little throughout evolutionary 
time. Th ey include structures such as lipoproteins, lipopolysaccharides (LPS) 
of gram-negative bacteria, peptidoglycans of gram-negative and gram-
positive bacteria, and viral envelope glycoproteins. Th e PAMPs are recognised 
by pattern recognition receptors (PRRs) expressed by the cells of the innate 
immune system. PRRs are present on many types of innate immune cells and 
comprise several families such as Toll-like receptors (TLR), CD14, formyl 
peptide receptors, and complement receptors [Dempsey et al. 2003]. Of 
these, monocyte CD14 is a receptor for bacterial lipopolysaccharide (LPS). 
LPS binds to CD14 with the assistance of a LPS-binding protein (LBP). Th is 
may lead to appropriate activation of a cluster of receptors and eventually to 
the synthesis of infl ammatory mediators. Th e essential part of this activation 
pathway is the family of evolutionarily conserved transmembrane receptors, 
Toll-like receptors (TLRs). Of these, TLR-4 signals the presence of LPS 
aft er LPS has connected to it with the help of LBP. TLR-4 then activates the 
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transcription factor NFκB, which in turn activates genes encoding proteins 
involved in defence against infection [Wright et al. 1990, Poltorak et al. 
1998], reviewed in Fujihara et al. [2003]. 
6.1.1 Infl ammatory cells
All the cellular elements of the blood derive ultimately from the same 
cells–the pluripotent haematopoietic stem cells in the bone marrow. Th ese 
give rise to stem cells of more limited potential, which are the immediate 
progenitors of, for instance, the two main categories of white blood cells, the 
myeloid and the common lymphoid progenitors. Th e myeloid progenitor 
is the precursor of the granulocytes (neutrophils, eosinophils, basophils), 
macrophages, dendritic cells, and mast cells of the innate immune system, 
whereas the common lymphoid progenitor gives rise to the lymphocytes 
and to the natural killer cells [Janeway et al. 2005]. Eosinophils, basophils, 
and mast cells are, for example, responsible for the defence against parasitic 
infections and are involved in allergic reactions [Bochner and Schleimer 
2001]. Natural killer cells recognise abnormal cells such as those infected 
with a virus– thus inducing apoptosis [Yokoyama et al. 2004].
Th e cells involved in the acute infl ammatory response are phagocytes 
(monocytes, macrophages, polymorphonuclear neutrophils) and 
lymphocytes. Phagocytic cells bind to micro-organisms, internalise them, 
and then kill them. Upon phagocytosis, they produce a variety of other toxic 
products that help kill the engulfed micro-organism. Th e most important of 
these are nitric oxide, the superoxide anion, and hydrogen peroxide (H2O2), 
all of which are directly toxic to bacteria. Superoxide is generated by a 
multicomponent, membrane-associated NADPH oxidase in a process known 
as the respiratory burst because it is accompanied by a transient increase 
in oxygen consumption. Ultimately, superoxide is converted into H2O2 by 
the enzyme superoxide dismutase. Macrophages can ingest pathogens and 
produce the respiratory burst immediately when encountering an infecting 
micro-organism, and this can be suffi  cient to prevent an infection from 
becoming established [Janeway et al. 2005].
6.1.1.1 Monocytes and macrophages  
Monocytes circulating in the blood are relatively inactive but upon migration 
into the tissues diff erentiate continuously into active phagocytosing 
macrophages. Th e majority of circulating monocytes express membrane-
bound CD14 (mCD14), an LPS receptor which mediates monocyte activation 
via TLR-4 [Wright et al. 1990, Poltorak et al. 1998]. Two soluble forms of 
CD14 (sCD14) are constitutively generated: one through liberation from 
glycosylphosphatidylinositol (GPI) anchoring, and the other by proteolytic 
cleavage by a serine protease [Bufl er et al. 1995]. Expression of mCD14 and 
release of sCD14 are regulated by cytokines and bacteria. Interleukin-4 (IL-4) 
and IL-10 reduce levels of mCD14 and sCD14, whereas interferon-γ (IFNγ), 
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tumour necrosis factor (TNF), and bacterial ligands cause their upregulation 
(reviewed in Landmann et al. [2000]). Low mCD14 levels occur in patients 
with sepsis [de Werra et al. 2001], but the importance of the downregulation 
of mCD14 is unknown [Bazil and Strominger 1991, Ertel et al. 1993].
Th e phenotypic form taken by a macrophage depends on the 
environmental factors present in the tissue [Duffi  eld 2003]. Macrophages 
exist in especially large numbers in connective tissue, in the submucosal 
layer of the gastrointestinal tract, in the lung (in both the interstitium 
and the alveoli), along certain blood vessels in the liver (Kupff er cells), 
and in the spleen where they remove senescent blood cells. Th e cytokines 
secreted by macrophages in response to pathogens are a structurally 
diverse group of molecules that include IL-1β, IL-6, IL-12, TNFα, and the 
chemokine IL-8 (also called CXCL8). In addition to cytokine production 
and phagocytosis, macrophages and closely related dendritic cells are highly 
effi  cient in presenting antigens to CD4-positive T cells via class II major 
histocompatibility (MHC) antigen complex, such as the human leukocyte 
antigen, HLA-DR. In patients with sepsis, a decrease in HLA-DR expression 
[Docke et al. 1997] leads to impaired antigen presentation capacity which 
suppresses helper T-cell activation [Wolk et al. 2000]. Decreased HLA-DR 
expression is associated with adverse outcomes including septic complications 
and increased mortality [Tschaikowsky et al. 2002, Mentula et al. 2003].
6.1.1.2 Neutrophils
Polymorphonuclear neutrophils (PMN) are the most numerous leukocytes in 
the blood but are not present in normal, healthy tissues. Cytokines produced 
by phagocytes upon the activation of the innate immune system induce 
leukocytosis, which mainly is due to an increase in circulating neutrophils. 
Th ese neutrophils derive from two sources: from the bone marrow where 
they are produced, and from the sites in blood vessels where they are 
attached loosely to endothelial cells. Each neutrophil has a multilobed 
nucleus and contains granules and secretory vesicles [Borregaard and 
Cowland 1997]. Peroxidase-positive (azurophilic or primary) granules carry 
myeloperoxidase; azurophilic granules are particularly active in the digestion 
of phagocytosed material. Th e peroxidase-negative granules are classed as 
specifi c (secondary) and gelatinase (tertiary) granules. Th is classifi cation is 
based on their relative content of lactoferrin and gelatinase. Specifi c granules 
play important roles in initiating the infl ammatory response. Additionally, 
there are secretory vesicles which are important reservoirs of membrane 
proteins such as CD11b/CD18. Th ese membrane proteins, upon activation, 
become incorporated into the plasma membrane of neutrophils [Todd et al. 
1984, Witko-Sarsat et al. 2000].
Neutrophils have surface receptors for formyl peptides, which are derived 
from and are specifi c to bacterial metabolism, and for complement-derived 
C5a. CD11b/CD18 receptors mediate neutrophil binding to the bacterial 
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surface opsonised with complement, i.e., iC3b molecules on the bacterial cell 
wall. In addition to complement components, the microbes are opsonised 
with antibodies. Neutrophils have Fcγ receptors (FcγIII receptor or CD16 
and FcγII receptor or CD32), which bind to the Fc-portion (the tail) of the 
antibody molecule on the bacterial cell wall [Brown et al. 2006].
6.1.1.3 Lymphocytes  
Lymphocytes are responsible for the specifi c recognition of pathogens and 
initiation of adaptive immune responses. Th e characteristic of adaptive 
immunity is the use of antigen-specifi c receptors on T and B cells to drive 
targeted eff ector responses. B and T lymphocytes develop from progenitor 
cells within the bone marrow; B cells remain within the marrow for the 
duration of their development, but T cells migrate to the thymus at an 
early stage as thymocytes [Parkin and Cohen 2001]. For naive T cells to be 
activated by antigen, the antigen must be bound to an MHC molecule on an 
antigen-presenting cell that also expresses co-stimulatory molecules. 
Th e diff erentiation of naïve CD4+ T cells into diff erent subclasses of 
eff ector T cells is infl uenced by cytokines elicited by the pathogen. Many 
pathogens, especially intracellular bacteria and viruses, activate dendritic 
cells and natural killer cells to produce IL-12 and IFNγ, which then cause 
proliferating CD4+ T cells to diff erentiate into TH1 cells. IL-4, which can 
be produced by various cells, is produced in response to parasitic worms 
and other pathogens and acts on proliferating CD4+ T cells to cause them 
to become TH2 cells. Th e two subsets of CD4+ T cells–TH1 and TH2–have 
very diff erent functions: TH2 cells are the most eff ective activators of B cells, 
especially in primary responses, whereas TH1 cells are crucial for activating 
macrophages and are also involved in directing the production of certain 
antibody isotypes [Dempsey et al. 2003]. 
6.1.2 Phagocyte-endothelial cell interaction
Th e recruitment of activated phagocytes to sites of infection is one of the 
most important functions of innate immunity. Recruitment occurs as part 
of the infl ammatory response and is mediated by cell-adhesion molecules 
induced on the surface of the local blood vessel endothelium (Fig. 1).
Th ree families of adhesion molecules are important for leukocyte 
recruitment. Th e selectins are membrane glycoproteins with a distal 
lectin-like domain that binds specifi c carbohydrate groups. Th ree types of 
selectins comprise one on endothelial cells (E-selectin), one on leucocytes 
(L-selectin), and one on platelets (P-selectin). E-selectin is induced on 
activated endothelium. Selectins initiate endothelium–leukocyte interactions 
(rolling; Fig. 1) by binding to the fucosylated oligosaccharide ligands 
on leukocytes passing by. Th e subsequent tighter adhesion is due to the 
binding of intercellular adhesion molecules (ICAMs) on the endothelium to 
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heterodimeric proteins of the integrin family on leukocytes. Th e leukocyte 
integrins important for extravasation are leukocyte functional antigen-1 
(LFA-1, also known as CD11a/CD18) and CR3 (complement receptor type 
3, also known as CD11b/CD18 or Mac-1), and they both bind to ICAM-1. 
Strong adhesion between leukocytes and endothelial cells is promoted by 
the induction of ICAM-1 on infl amed endothelium and the activation of 
a conformational change in LFA-1 and CD11b/CD18 that occurs in the 
response to chemokines, among other leukocyte-activating agents [Repo 
and Harlan 1999]. 
Activation of endothelium is driven by interactions with macrophage 
cytokines, particularly TNFα, which induce the rapid externalisation of 
granules called Weibel–Palade bodies in the endothelial cells. Th ese granules 
contain preformed P-selectin, which is thus expressed within minutes 
on the surface of local endothelial cells aft er the production of TNFα by 
macrophages. Shortly aft er the appearance of P-selectin on the cell surface, 
mRNA encoding E-selectin is synthesised, and within 2 hours, the endothelial 
cells are expressing mainly E-selectin. Both these proteins interact with the 
sulfated-sialyl-Lewisx that is present on the surface of neutrophils. 
Resting endothelium carries low levels of ICAM-2, apparently in all 
vascular beds. Th is may be used by circulating monocytes to navigate out 
of the vessels and into their tissue sites. Th is monocyte migration happens 
continuously and essentially ubiquitously. However, upon exposure to TNFα, 
local expression of ICAM-1 is strongly induced on the endothelium of small 
vessels near or within the infectious focus. ICAM-1 in turn binds to LFA-1 or 
CD11b/CD18 on circulating monocytes and polymorphonuclear leukocytes, 
in particular neutrophils [Ebnet and Vestweber 1999]. 
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Figure 1. Monocytes circulating in the blood recognise peripheral venule walls near 
sites of infl ammation and leave the bloodstream to migrate into the tissue toward the 
site of infection and infl ammation. Th e initial interactions are mediated by adhesion 
molecules that fi rst capture the monocyte from the bloodstream and cause it to adhere 
to the vascular endothelium. Chemokines bound to the vascular endothelium then 
signal the monocyte to migrate across the endothelium into the underlying tissue. Th e 
monocyte, now diff erentiating into a macrophage, continues to migrate, under the 
infl uence of chemokines released during infl ammatory responses, toward the site of 
infection (adopted from Janeway et al. [2005]). 
6.1.3 Local infl ammation
Infl ammation plays three essential roles in combating infection. Th e fi rst is to 
deliver additional eff ector molecules and cells to sites of infection, to augment 
the killing of invading micro-organisms by the front-line macrophages. Th e 
second is to provide a kind of physical barrier in the form of microvascular 
coagulation to prevent the spread of the infection in the bloodstream. Th e 
third is to promote the repair of injured tissue [Janeway et al. 2005].
Infl ammation has three main components: an increased blood supply to 
the area, bringing leucocytes and serum molecules to the aff ected site; an 
increased capillary permeability allowing exudation of the serum proteins 
(antibody, complement, kininogens) required to control the infection. 
Th ese two processes account for the heat, redness, and swelling. Finally, an 
increase in leukocyte migration into the tissue, together with the release 
of bradykinins and prostaglandins, accounts for the pain. Neutrophils are 
the fi rst cells entering the sites of acute infl ammation caused by infection, 
but from the fi rst days onwards, mononuclear phagocytes and activated 
lymphocytes start to arrive. Th e outcome of an acute reaction depends on 
whether the antigen or the infectious agent is cleared. Th e infectious agent 
can be destroyed by neutralisation with specifi c antibodies or complement 
(antibodies bind to a bare particle and prevent it from infecting cells, or 
Monocyte
Activation  of 
















they introduce it to a phagocyte), phagocytosis (the micro-organism is 
internalised and degraded in a phagosome), or cytotoxic reactions (contents 
of cytoplasmic granules are secreted to resist the micro-organisms of the 
infected cell) [Roitt et al. 2002]. Four major plasma enzyme systems play an 
important role in haemostasis and control of infl ammation. Th ese are the 
clotting system, the fi brinolytic (plasmin) system, the kinin system, and the 
complement system. Th e loss of local control or an overly activated response 
may result in an exaggerated systemic response. 
6.1.4 Soluble mediators of infl ammation 
An infl ammatory response is induced by a variety of infl ammatory mediators 
released as a consequence of the recognition of pathogens by macrophages. 
Th ese infl ammatory mediators include prostaglandins, leukotrienes, and 
platelet-activating factor, all of which are rapidly produced by macrophages 
through enzymatic pathways that degrade membrane phospholipids. Th eir 
actions are followed by those of the chemokines and cytokines that are 
synthesised and secreted by macrophages in response to pathogens. Another 
way in which pathogen recognition rapidly triggers an infl ammatory 
response is through activation of the complement cascade, which includes 
facilitation of phagocytosis and generation of potent cleavage products 
such as C5a. C5a is engaged in the increase in vascular permeability and 
induction of the expression of some adhesion molecules and also acts as a 
powerful chemoattractant for neutrophils and monocytes. C5a also activates 
phagocytes and local mast cells, which are in turn stimulated to release 
their granules containing the small infl ammatory molecule histamine and 
the cytokine TNFα.
Cytokines
Cytokines are small proteins (approximately 25 kDa) that are released 
by various cells, usually in response to an activating stimulus, and they 
induce responses through binding to specifi c receptors. Th ey can act in 
an autocrine manner, aff ecting the behaviour of the cell that releases the 
cytokine; and act in a paracrine manner, aff ecting the behaviour of adjacent 
cells. Some cytokines are even suffi  ciently stable to act in an endocrine 
manner, aff ecting the behaviour of distant cells. Th e two major structural 
families of cytokines are the haematopoietin family, which includes growth 
hormones and also many interleukins with roles in both adaptive and 
innate immunity; and the TNF family, which functions in both innate 
and adaptive immunity and includes many members that are membrane-
bound. Cytokines with chemoattractant activity are called chemokines, 
those that cause diff erentiation and proliferation of stem cells are called 
colony-stimulating factors, and those that interfere with viral replication 
are called interferons. Th e cytokines have been divided into pro- and anti-
infl ammatory depending on their principal actions, but since the cytokines 
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act as a network with various feedback systems, the overall eff ect depends 
on the context and possibly also on local cytokine concentration [Dinarello 
2000, Opal and DePalo 2000].  
TNFα is the primary mediator of sepsis and is derived mainly from 
activated macrophages and dendritic cells. It induces changes in vascular 
endothelium (expression of cell-adhesion molecules, loosening of cell–cell 
junctions with increased fl uid loss, and induction of local blood clotting). 
TNFα is an inducer of local infl ammatory response. TNFα also plays 
a role in stimulating the migration of dendritic cells from their sites in 
peripheral tissues to the lymph nodes and in their maturation into antigen-
presenting cells. Its systemic release causes vasodilatation, which leads to a 
drop in blood pressure, increased vascular permeability leading to a drop 
in plasma volume, and eventually to shock. According to Selby et al., the 
administration of recombinant human TNFα was found to result in rigors, 
fever, and tachycardia within 20 minutes to 2 hours aft er the beginning 
of infusion, with hypotension in a dose-dependent manner following 6 
to 12 hours aft er TNFα. Leukocytosis, elevated serum creatinine kinase 
levels and increased CRP concentration were also induced. Th e half-life of 
TNFα was extremely short, only 17 minutes [Selby et al. 1987]. Th e other 
cytokine involved in the pathogenesis of septic shock is IL-1, which acts 
synergistically with TNFα. Of the two forms of IL-1, α and β [March et 
al. 1985], only IL-1β has been detected in plasma of patients with sepsis 
[Casey et al. 1993]. Th e short elimination time of TNFα and methodological 
problems in the determination of IL-1β hamper their use in clinical studies 
[Th ijs and Hack 1995]. 
Interleukin-6
IL-6 is produced in response to IL-1β by macrophages, dendritic and glial 
cells, skeletal muscle cells, adipocytes, endothelial and intestinal epithelial 
cells. Locally, it induces lymphocyte activation and increased antibody 
production. Together with TNFα and IL-1β, it induces the production of acute 
phase proteins in the liver and induces fever, which favours eff ective host 
responses in many ways. IL-6 has both pro- and anti-infl ammatory eff ects 
[Fink 2006]. According to van Gameren et al., intravenous administration of 
recombinant human IL-6 to cancer patients induces fever, chills, leukocytosis, 
and anaemia and increased serum C-reactive protein (CRP)- and amyloid 
A levels [van Gameren et al. 1994]. High levels of circulating IL-6 appear in 
experimental human endotoxaemia [van Deventer et al. 1990] and in sepsis 
patients [Damas et al. 1992].
Interleukin-8
IL-8 (recently renamed, being a member of the chemoattractant family, as 
CXCL8) is a chemoattractant for neutrophils. All the chemokines are related 
in amino acid sequence, and their receptors are all integral membrane 
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proteins containing seven membrane-spanning helices. Chemokines 
function mainly as chemoattractants for leukocytes: recruiting monocytes, 
neutrophils, and other eff ector cells from the blood to sites of infection, for 
example, by regulating adhesive responses of immune cells [Laudanna et 
al. 2002]. IL-8 can be produced by many diff erent cell types. It mobilises, 
activates, and degranulates neutrophils and also induces angiogenesis. In 
an in vitro experiment, IL-8 could mediate acute-phase protein production 
by human hepatocytes [Wigmore et al. 1997]. Elevated levels of IL-8 have 
been detected in sepsis patients [Lin et al. 1994, Fujishima et al. 1996].
Soluble IL-2Rα 
IL-2 is made by T cells, some B cells, and dendritic cells.  It is required 
for the proliferation of CD8+ T (cytotoxic) cells [Gaff en and Liu 2004]. 
Th e IL-2 receptor (IL-2R) is composed of three subunits, α, β, and γc. A 
soluble form of IL-2Rα is released upon cell activation, denoting activation of 
T-lymphocytes [Rubin et al. 1985, Rubin and Nelson 1990]. Elevated levels of 
sIL-2Rα have been detected in patients with sepsis [Takala et al. 1999a].
6.1.5 Systemic infl ammation
Systemic infl ammation is characterised by the activation of infl ammatory 
cells, of the coagulation system, and of the complement system, all occurring 
in the circulation. As the noxious stimulus is being resolved, proinfl ammatory 
mediators are produced, and anti-infl ammatory mediators control the 
infl ammatory response. However, in some cases, no homeostasis is achieved. 
Th e eff ects of infl ammatory mediators become destructive, and the systemic 
infl ammatory response may proceed to hypotension and circulatory collapse, 
and to the development of injury in distant organs [Cohen 2002, Annane 
et al. 2005]. A recent hypothesis postulates that in the case of sepsis, i.e., 
infection with systemic infl ammation, the phases of enhanced infl ammation 
can alternate with periods of immune suppression [Xiao et al. 2006]. 
Corticosteroid drugs, powerful anti-inflammatory agents, are 
pharmacological derivatives of members of the glucocorticoid family of 
steroid hormones. Cortisol acts through intracellular cortisol-binding 
receptors expressed in almost every cell of the body. Th ese receptors regulate 
the transcription of specifi c genes, either by direct binding to hormone-
response elements in the promoters of various genes, or by regulating gene 
expression through interaction with other transcription factors, such as 
NF-κB. Th e gene interference then leads to eff ects on infl ammatory processes, 
which include cessation of the production of infl ammatory mediators, 
including cytokines, prostaglandins, and nitric oxide; the inhibition of 
infl ammatory cell migration to sites of infl ammation by inhibition of the 
expression of adhesion molecules; and an increase in the death of leucocytes 
and lymphocytes by apoptosis [Barnes 1998, Guyre and Munck 1999].  
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6.1.6 Acute phase response
Th e acute-phase response includes a large number of behavioural, 
physiological, biochemical, and nutritional changes. Biochemical changes 
include changes in the concentrations of many plasma proteins, known as 
the acute-phase proteins. An acute-phase protein (APP) has been defi ned as 
a plasma protein whose concentration increases (positive APPs) or decreases 
(negative APPs) by at least 25% as a response to infl ammation. Th e proteins 
whose production is induced by cytokines in the liver include C-reactive 
protein (CRP), [Gabay and Kushner 1999], procalcitonin (PCT) [Nijsten et 
al. 2000], and sCD14 [Bas et al. 2004]. 
C-reactive protein
IL-6 induces CRP synthesis in the liver [Castell et al. 1988, Wigmore 
et al. 1997]. CRP, a member of the pentraxin protein family, binds to 
the phosphocholine portion of certain bacterial and fungal cell-wall 
lipopolysaccharides [Povoa 2002]. CRP is able to opsonise bacteria, thus 
activating the complement cascade. CRP is currently the most widely used 
laboratory test for the evaluation of the acute-phase response. Aft er the insult 
eliciting systemic infl ammation, CRP levels start to rise in 6 to 10 hours 
and peak within 24 to 48 hours [Anonymous 1988]. Among patients with 
CRP concentrations above 100 mg/l, 80 to 85% have a bacterial infection 
[Morley and Kushner 1982].
Procalcitonin
PCT, a 14 kDa propeptide of calcitonin, is normally produced in the C-cells 
of the thyroid gland [Jacobs et al. 1981]. Normally, only a very few PCT 
molecules are released into the circulation, and plasma PCT levels in healthy 
humans are approximately 5 to 50 ng/l. PCT has an intermediate half-life 
of approximately 22 to 33 h in serum. PCT is a novel marker of infection 
[Assicot et al. 1993, Meisner 2002]. During an infl ammatory response, PCT 
has been shown to originate from hepatocytes [Nijsten et al. 2000]. Aft er the 
administration of endotoxins to healthy volunteers, plasma PCT level began 
to rise aft er 4 hours, peaked at 6 h, and remained near its peak level for up 
to 24 h [Dandona et al. 1994]. Whether PCT has anti- or proinfl ammatory 
eff ects remains unanswered [Monneret et al. 2003]. 
Soluble CD14  
Monocyte mCD14, the receptor for the LPS-LBP complex, promotes 
intracellular signalling via TLR-4, which induces NFκB activation. Th e 
cleavage product of mCD14 exists in soluble form (sCD14) within the 
circulation. Soluble CD14 also binds bacterial structures [Blondin et al. 
1997]. Many cells, among them epithelial and endothelial cells, express no 
mCD14. Th e activation of these cells by microbial structures involves sCD14 
molecules [Pugin et al. 1993]. Soluble CD14 may enhance an mCD14-positive 
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cell-response to bacterial structures [Dziarski et al. 2000] and contribute 
to elimination and detoxifi cation of bacterial endotoxins [Yu et al. 1997], 
also by transferring cell-bound LPS to plasma lipoproteins [Kitchens et al. 
2001]. In addition to those functions, it is thought to be an APP, due to its 
cytokine-induced production by hepatocytes [Su et al. 1999, Bas et al. 2004]. 
Increased levels of sCD14 occur in patients with infection [Landmann et al. 
1995, Burgmann et al. 1996, Wenisch et al. 1996, Carrillo et al. 2001].
6.2 COMMUNITY-ACQUIRED INFECTION
Community-acquired infection is defi ned as the absence of circumstances 
and predisposing factors defi ning a nosocomial infection. Th e exact 
defi nition varies among studies. Usually the criteria include the absence 
of any hospitalisation within the previous 2 weeks, for example, [Valles 
et al. 2003], surgery, or major trauma. Nosocomial, i.e., hospital-acquired 
infection, is defi ned as an infection for which no evidence exists that the 
infection was present or incubating at the time of hospital admission. Th e 
infl uence of previous hospitalisation is defi ned case-by-case. Each infection 
is to be assessed individually for evidence that links it to hospitalisation 
[Garner et al. 1988]. 
As a third category, the concept of health-care-associated infection has 
been proposed; this applies to the elderly living in care homes, nursing homes, 
and rehabilitation centres, and to patients receiving dialysis or chemotherapy, 
and it is reported to have similarities with nosocomial infections in terms 
of frequency of various comorbid situations, source of infection, pathogens 
and their susceptibility patterns, and mortality rate at follow-up due to the 
usage of catheters and other body boundary-breaking devices [Friedman 
et al. 2002, Kollef et al. 2005, Shorr et al. 2006]. 
Clinical criteria of systemic infl ammation
To improve the diagnostics of infection, clinical criteria of systemic 
infl ammation were developed [Bone et al. 1992] (Table 1) and later re-
evaluated [Levy et al. 2003] by the 2001 International Sepsis Defi nitions 
Conference. In the re-evaluation process, the exact defi nition of sepsis was 
still recognised as unattainable; therefore, to enhance the sensitivity of the 
concept, the meeting focused on listing all the possible indicators of sepsis. 
Furthermore, presence of infection was included as verifi ed or suspected.
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Table 1. Defi nitions for infection, systemic infl ammatory response syndrome, and 
sepsis according to the ACCP/SCCM Consensus Conference [Bone et al. 1992]
Infection = a pathologic process caused by the invasion of normally sterile tis-
sue of fl uid or the body cavity by pathogenic or potentially pathogenic micro-
organisms.
Systemic infl ammatory response syndrome (SIRS) = the systemic infl ammato-
ry response to a variety of severe clinical insults. Th e response is manifested by 
two or more of the following conditions: 1. temperature > 38°C or < 36°C; 2. 
heart rate > 90/min; 3. respiratory rate > 20 breaths/min or PaCO2 < 32 mmHg 
(4.3 kPa); 4. white blood cell count > 12 x109/l, < 4 x109/l or >10% immature 
band forms.
Sepsis = systemic response, SIRS, to infection
Severe sepsis = sepsis associated with organ dysfunction, hypoperfusion, or 
hypotension. Hypoperfusion and perfusion abnormalities may include, but are 
not limited to, lactic acidosis, oliguria, or an acute alteration in mental status.
Septic shock = sepsis-induced hypotension despite adequate fl uid resuscitation 
along with the presence of perfusion abnormalities that may include, but are 
not limited to, lactic acidosis, oliguria, or an acute alteration in mental status.
Sepsis-induced hypotension = a systolic blood pressure < 90 mmHg or a 
reduction of ≥ 40 mmHg from baseline, in the absence of other causes of hypo-
tension.
Multiple organ dysfunction syndrome (MODS) = presence of altered organ 
function in an acutely ill patient such that homeostasis cannot be maintained 
without intervention.
Bloodstream infection (BSI) is traditionally defi ned as an acute illness 
due to an infection, in which the pathogen(s) spread to the circulation, 
either transiently or more prevalently, and thus can be confi rmed in the 
laboratory by culture of pathogens from the blood sample [Weinstein et al. 
1983a, 1983b]. BSI accompanied by a systemic infl ammatory response is 
defi ned as sepsis. Primary BSI is a situation in which the pathogen isolated 
from blood culture is unrelated to an infectious focus elsewhere in the 
body, whereas in a secondary BSI, a pathogen isolated from blood culture is 
associated with an infection at another site [Garner et al. 1988]. However, it 
is possible for a patient to have severe sepsis with altered organ function such 
as disorientation, hypoxemia, metabolic acidosis, and oliguria without the 
presence of bacteria in any blood culture sample. Th is situation was earlier 
referred to as blood culture-negative sepsis.
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Respiratory infections
Of the CAIs in an emergency department (ED), are respiratory tract 
infections are the most common. Diff erentiating pneumonia from other 
lower respiratory tract infections relies on radiological fi ndings which may 
not always be present on admission. In the case of (suspected) pneumonia, 
identifi cation of the causative agent is mainly based on blood cultures. 
Community-acquired pneumonia (CAP) is defi ned by a new infi ltrate in 
the on-admission chest x-ray together with compatible clinical features 
supporting the diagnosis of pneumonia, including symptoms of lower 
respiratory tract infection (LRTi), and fever [File 2003]. 
LRTi is defi ned as an acute illness presenting with cough and at least 
one other symptom such as sputum production, dyspnoea, wheeze, chest 
discomfort/pain, without any alternative explanation (sinusitis, pharyngitis, 
or a new presentation of asthma) [Macfarlane et al. 2001]. Without the new 
infi ltrate on chest x-ray, these symptoms are non-specifi c, and beside LRTi, 
may also be present in patients with upper respiratory tract infections, 
with chronic bronchitis; and with non-infectious diseases such as reactive 
airways disease, atelectasis, congestive heart failure, vasculitis, pulmonary 
embolism, or malignant disease. 
6.3 INFECTION DIAGNOSTICS
6.3.1 Abnormal body temperature
Elevation of body temperature is caused mainly by TNFα, IL-1β, and 
IL-6. Th ese are termed endogenous pyrogens because they cause fever and 
derive from an endogenous source rather than from bacterial components 
such as LPS, which is an exogenous pyrogen. Th ese cytokines act on the 
hypothalamus, altering the body’s temperature regulation, and on muscle 
and fat cells, altering energy mobilisation to elevate body temperature. At 
elevated temperatures, bacterial and viral replication decrease, and the 
adaptive immune response is enhanced. Host cells are also protected from 
the deleterious eff ects of TNFα at elevated temperatures (reviewed by Hasday 
et al. [2000]).
Abnormal body temperature, i.e., fever or hypothermia, is a major clinical 
fi nding associated with systemic infl ammation and is one of the criteria of 
SIRS. In patients with infection, abnormal body temperature and chills are 
common. Elderly patients in particular may, however, develop infection and 
BSI without fever [Gleckman and Hibert 1982, Fontanarosa et al. 1992], and 
those signs and symptoms considered typical for infection appear irregularly 
[Chassagne et al. 1996]. A BSI without fever has been associated with poor 
prognosis [Ispahani et al. 1987; Weinstein et al. 1983a, 1997].
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Abnormal body temperature is included in the defi nition of systemic 
infl ammatory response syndrome (SIRS, Table 1). As the re-evaluation 
conference concluded, the SIRS criteria had proved to be sensitive but not 
specifi c to infection [Jaimes et al. 2003, Levy et al. 2003]. Th e presence of SIRS 
criteria alone was not prognostic for mortality [Stoiser et al. 1998], not even 
in ED patients with suspected infection [Shapiro et al. 2006]. Beside infection, 
SIRS is associated with major trauma, burns, pancreatitis, haemorrhagic 
shock, and exogenous administration of cytokines. SIRS may, however, even 
occur in patients without any measurable systemic infl ammation [Takala et 
al. 1999b]. Dr. Bone, the inventor of the concept, underlined the importance 
of the context in which SIRS is used, never encouraging its use as a stand-
alone defi nition [Dellinger and Bone 1998]. 
6.3.2 Blood culture
Blood culture is an essential laboratory examination when severe infection 
is suspected. Sometimes, for example, in acute illness causing generalised 
symptoms, it may also be used to rule out systemic infection. No general 
recommendation exists as to the frequency at which blood culture samples 
should be drawn, but a common practise is that the proportion of samples 
revealing growth should be approximately 10% of the total number of 
samples drawn [Aronson and Bor 1987, Washington 1992, Mylotte and 
Tayara 2000]. At Helsinki University Central Hospital (HUCH) the annual 
number of blood cultures has been rising (in 2001, 7761 samples vs. 2006 
with 9125). Since 2001 the percentage of positive blood cultures has ranged 
from 6.6 to 8.2% (personal communication, Head of Department, Docent 
Petteri Carlson, HUSLAB/Bacteriology).
According to the blood culture guidelines of the Laboratories of the 
Hospital District of Helsinki and Uusimaa (HUSLAB), a blood sample of 
10 ml is drawn for the aerobic and anaerobic culturing media. Th e skin 
is carefully decontaminated at the site of sampling in order to avoid false 
positive results. Normally, the sampling procedure is repeated aft er 30 
minutes. In suspected endocarditis the number of samples is double. A 
positive result is reported as soon as any bottle reveals growth. Th is usually 
takes at least 1 or 2 days. Th e negative result is reported 6 days aft er sampling, 
if no slowly growing specimen is suspected [Anonymous 2006a]. 
A positive blood culture is not always clinically signifi cant, since 
contamination may occur, or the positive result may represent the transient 
and self-limited presence of micro-organisms in the blood. On the other 
hand, signifi cant pathogens may be leaking from the site of infection into 
the circulation only periodically and may therefore be harder to detect (false 
negative result). Th e blood culture may incorrectly appear negative also if 
(intravenous) antimicrobial therapy has been administered before sampling. 
Th e clinical signifi cance of the positive blood culture result depends on the 
pathogen, on the number and type of positive blood culture bottles compared 
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with the total number of bottles, and on the whole clinical picture: the 
patient’s clinical history, physical fi ndings, body temperature at the time of 
blood culture, results from cultures of specimens from other sites, imaging 
results, histopathologic fi ndings, and clinical course and response to therapy 
[Yagupsky and Nolte 1990].
In general, a BSI verifi ed by a positive blood culture is a sign of poor 
prognosis [Bryan 1989] and predisposes patients to vascular hypotension 
and shock [Bossink et al. 2001] with high mortality rates. Bacteraemia of 
unknown origin has been independently associated with fatal outcome 
[Leibovici et al. 1992, Reyes et al. 1999]. In the European SOAP study in 
multivariate analysis, a bloodstream infection had an OR of 1.7 (95% CI 
1.2-2.4) for ICU mortality of sepsis patients and was an independent risk 
factor for death [Vincent et al. 2006]. However, for an occult bacteraemia 
verifi ed in patients already discharged from the ED, delayed initiation of 
antimicrobial chemotherapy did not aff ect outcome [Epstein et al. 2001]. 
Th e incidence and the total number of deaths due to BSIs has been 
increasing [Weinstein et al. 1983a, 1983b, 1997], particularly in older people, 
in hospitalised patients, and in patients treated in intensive care units [Kuikka 
1999]. In the 1990s, in one report half of all BSI episodes confi rmed by 
positive blood culture were nosocomial, with a quarter having no recognised 
source [Weinstein et al. 1997]. Th e incidence of the causative organism has 
changed over the years; in the 1930s, the most common cause of bacteraemia 
was Streptococcus pneumoniae; in the 1950s, Staphylococcus aureus, and by 
the 1960s, gram-negative rods, while in the 1980s, gram-positive cocci led 
in the statistics [Kuikka 1999]. According to the statistics of the National 
Public Health Institute of Finland, in all reported blood cultures during 
the last 10 years, the most common species found in patients aged 15 to 64 
years were Escherichia coli, Staphyloccus aureus, and other Staphylococcus 
species, followed by Streptococcus pneumoniae; and in patients aged > 65 
years were Escherichia coli, Staphyloccus aureus and other Staphylococcus 
species followed by Klebsiella species [Anonymous 2006b].
6.3.3 Markers of systemic infl ammation
In acutely ill patients, diff erentiating between infection and other causes 
of acute illness relies on the “whole picture,” i.e., the results of clinical and 
laboratory examinations including markers of systemic infl ammation. One 
of the fi rst indicators is the rise in the number of circulating leukocytes 
(leukocytosis) largely due to the demargination of neutrophils adhered to 
the endothelium of the blood vessels, for instance in the lungs, and also due 
to the mobilisation of bone marrow neutrophils [Mandell et al. 2005]. An 
exaggerated response to an infection may result in a vigorous consumption 
of leukocytes due to transmigration to the tissues and may therefore lead to 
leukopenia. Leukopenia [Valles et al. 2003], leukocytosis [Gleckman and 
Hibert 1982, Bossink et al. 1999], or, in general, an abnormal leukocyte 
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(white blood cell, WBC) count  [Oberhoff er et al. 1999, Guven et al. 2002,] 
indicates the possibility of bacterial infection underlying the acute systemic 
infl ammatory response. Leukocytosis can also occur aft er tissue damage, 
in acute gout, or in acute myocardial infarction [Remskar et al. 2002]. In 
such cases, microscopy of a blood smear could help: a rise in the number 
of circulating young neutrophils, i.e., the band forms a proportion > 10%, 
is an indicator of bacterial infection and therefore is included in the SIRS 
criteria [Bone et al. 1992, Levy et al. 2003]. Metabolic changes detectable 
in severe sepsis include increased blood lactate concentration, which seems 
to result, among other reasons, from limited tissue oxygenation and from 
increased glycolysis. Lactate measurement in an ED is not useful, due to 
technical problems [Mandell et al. 2005]. 
Th e measurement of serum levels of CRP is currently the most widely 
used means in evaluation of the acute phase response. Elevated levels are 
detectable in bacterial infections [Morley and Kushner 1982, Harbarth et al. 
2001, Chan et al. 2004, Sierra et al. 2004, Simon et al. 2004]. In patients with 
suspected CAP, elevated CRP levels can diff erentiate between an infectious 
and a non-infectious cause of an illness [Castro-Guardiola et al. 2000, 
Almirall et al. 2004]. Th e novel acute phase protein, PCT, has been very 
specifi c [de Werra et al. 1997, Bossink et al. 1999, Harbarth et al. 2001] and 
even better than CRP [Selberg et al. 2000, Persson et al. 2004, Simon et al. 
2004] in diff erentiating infection from sepsis. 
PCT has been useful in detecting infectious complications during 
postoperative periods [Aouifi  et al. 2000] and cardiogenic shock [Geppert 
et al. 2003, Clec’h et al. 2004]. PCT has aided in separating patients with 
atypical CAP from those with bacterial CAP [Hedlund and Hansson 2000]. 
In one ED setting, a PCT level as high as 0.6 μg/l was the most accurate 
for diagnosing bacterial CAI [Chan et al. 2004]. In patients with LRTi, 
antimicrobial therapy has been successfully reduced on the basis of PCT 
results [Christ-Crain et al. 2004]. Still, in elderly patients the levels of PCT > 
0.5 μg/l had only limited ability to distinguish between those with or without 
infection [Stucker et al. 2005]. In patients with organ dysfunction, both high 
CRP and high PCT may be associated with infection [Castelli et al. 2004]. 
Of the other soluble markers, elevated circulating levels of IL-6 [Hack et 
al. 1989, Damas et al. 1992, de Werra et al. 1997, Selberg et al. 2000, Harbarth 
et al. 2001] and IL-8 [Lin et al. 1994, Fujishima et al. 1996, Harbarth et 
al. 2001] have been detectable in patients with sepsis. Increased levels of 
sIL-2R have appeared in patients with CAP [Moussa et al. 1994], pancreatitis 
[Kylanpaa-Back et al. 2001b], and sepsis [Takala et al. 1999a]. High levels 
of sCD14 have appeared in patients with infection [Landmann et al. 1995, 
Burgmann et al. 1996, Wenisch et al. 1996, Carrillo et al. 2001].
Of the cellular markers, phagocyte CD11b expression levels peak within 
hours aft er the insult that elicits systemic infl ammation. Neutrophil CD11b 
has been upregulated in CAP [Glynn et al. 1999] and sepsis [Chishti et al. 
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2004], and aids in diff erentiating viral from bacterial infections as a part of a 
“clinical infection score” [Nuutila et al. 2006]. Both neutrophil and monocyte 
CD11b expression level are increased in patients with sepsis [Russwurm et 
al. 2002]. Despite its being a very sensitive and quickly responding marker of 
systemic infl ammation, phagocyte CD11b has not been specifi c for infection 
[Takala et al. 1996]. Trauma patients developing infection have shown a 
decrease in mCD14 expression level [Heinzelmann et al. 1996]. Patients 
with sepsis have been reported to present with decreased expression of 
mCD14 [de Werra et al. 2001], together with an increased level of sCD14 
[Gluck et al. 2001]. 
6.3.4 Prediction of the positive blood culture
Patients with a positive blood culture, i.e., bacteraemia, represent quite 
a heterogeneous population. Many of them have a clinically signifi cant 
infection, i.e., BSI, whereas in many the clinical signifi cance of bacteraemia 
is not so clear. False-negative cultures are hidden among the patients thought 
of as controls or the patients labelled as having a “possible infection.” A 
positive blood culture is a practical and clear endpoint and has been the gold 
standard for infection diagnostics research. Recognition of patients with BSI 
on admission to hospital is not feasible by any single clinical or laboratory 
variable [Peduzzi et al. 1992] or the clinical criteria of SIRS [Jones and Lowes 
1996, Bossink et al. 1999]. Many markers of systemic infl ammation have 
been reported to be associated with later verifi ed bacteraemia. Of the acute 
phase proteins, PCT, unlike CRP, predicted bacteraemia in an ED setting 
[Guven et al. 2002, Chan et al. 2004] and in patients with fever [Bossink 
et al. 1999]. PCT has been able to diff erentiate among bacteraemic, non-
bacteraemic bacterial, and viral infections [Rintala et al. 2001] and was 
higher in post-operative patients with bacteraemia [Aouifi  et al. 2000]. 
CRP is reported to have only limited diagnostic utility for the detection 
of bacteraemia [Adams 2005]. Of the other soluble markers, high levels of 
circulating IL-6 [Groeneveld et al. 2001] and IL-8 have been reported to 
predict bacteraemia [Lin et al. 2000]. In neutropenic patients with fever, 
PCT and IL-8 [Engel et al. 1999] and in neutropenic children with cancer 
presenting with fever, IL-6, IL-8, and sIL-2R have predicted bacteraemia 
similarly [Soker et al. 2001]. In another study PCT, CRP, IL-6, and IL-8 had 
comparable high negative predictive values (NPV), and comparable but low 
positive predictive values (PPV) for bacteraemia [Persson et al. 2004].  
Th e soluble receptor sCD14 [Burgmann et al. 1996], or the cell-associated 
receptors phagocyte CD11b [Kuuliala et al. 2004] and mCD14 [Ertel et 
al. 1993] have not been so intensively studied concerning specifi cally 
the prediction of bacteraemia. Many studies concerning prediction of 
bacteraemia with markers of systemic infl ammation have involved patients 
with cytopenia; thus it has been impossible to determine the density of 
cellular markers.
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6.4 OUTCOME OF PATIENTS WITH INFECTION
6.4.1 Clinical predictors of outcome 
Of patients with CAI, only a small percentage require evaluation and possible 
treatment at a tertiary care hospital, and even among these patients, a poor 
outcome is quite rare [Esel et al. 2003, Shapiro et al. 2006]. Poor prognosis is 
associated with several predisposing factors, of which the most important are 
age and the underlying disease and its severity [Kuikka 1999, van Langevelde 
et al. 2000]. Severity of the underlying disease has been characterised by 
evaluation of patients according to their estimated life expectancy. Four 
categories of disease severity were originally proposed by McCabe and 
Jackson, who described the underlying disease as rapidly fatal, ultimately 
fatal (within 4 years), or not fatal; or there even may be no underlying illness 
[McCabe and Jackson 1962]. Application of this division in a Finnish study 
of bacteraemic patients showed that mortality increases along with severity 
of the underlying disease [Kuikka 1999]. 
In patients with serious infections, a factor documented in several studies 
to be associated with poor prognosis is advanced age [Ruiz et al. 1999, 
van Langevelde et al. 2000, van de Beek et al. 2004, Roson et al. 2004]. In 
the elderly, decline in the quality of the fi rst line of defence (i.e., atrophy 
and dryness of the skin and mucous membranes), reduced vitality, and 
increased risk for trauma, together with retardation of the repair process, 
should probably be regarded as the major causes of increased susceptibility 
to infections [van der Meer and Kullberg 2002]. Certain changes in the 
infl ammatory response of the elderly include impaired production of 
proinfl ammatory cytokines in response to LPS stimulation [Bruunsgaard 
et al. 1999], but the clinical signifi cance of many fi ndings remains unknown 
[Cinader 1999, Pawelec 2006].
Several models have been developed for intensive care patients to score 
the severity of illness and predict their risk of death, including the Acute 
Physiology and Chronic Health Evaluation (APACHE II) [Knaus et al. 1985] 
and the Sepsis-related Organ Failure Assessment (SOFA) [Vincent et al. 
1996]. Most of these scoring systems have, however, been developed and 
validated only for intensive care units and therefore cannot be applied to 
the ED setting. APACHE II can be utilised for the fi rst 24 h, since aft er that 
time, many of the variables are infl uenced by the treatment. Additionally, 
the diff erent factors in the scoring systems can be interpreted diff erently 
with regard to predicting outcome. For example, when a patient is deeply 
unconscious but otherwise in a stable condition, prognosis is oft en poorer 
than the total score would imply.
Shapiro et al. [Shapiro et al. 2003] developed the fi rst prediction guidelines 
for the ED setting: the Mortality in Emergency Department Sepsis (MEDS) 
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score. In the derivation set of that study, independent multivariate predictors 
for death were terminal illness, tachypnea or hypoxia, septic shock, platelet 
count <150 000/l, band proportion > 5%, age > 65 yrs, LRTi, nursing home 
residence, and altered mental status. Points were assigned to each predictor 
in relation to the odds ratio given by multivariate analysis, allowing a MEDS 
score to be calculated. Th e resulting scores were grouped into fi ve risk 
groups from very low to very high. When applied to the validation set, this 
score successfully stratifi ed the patients into groups at increasing risk of 
death. Originally it was used for predicting 28-day mortality, but a recent 
report confi rmed its ability also for predicting 1-year mortality [Shapiro et 
al. 2007].
6.4.2 Laboratory predictors of outcome    
Leukopenia, i.e., diminished WBC count, is associated with a greater 
susceptibility to severe infections and with a poor prognosis [Valles et al. 
2003]. However, in one study of critically ill patients with suspected sepsis, 
WBC count had no prognostic value [Pettila et al. 2002]. CRP does not 
predict mortality [Smith et al. 1995] or organ failure [Takala et al. 1999a] 
when measured on admission, but is informative in follow-up [Smith et 
al. 1995, Takala et al. 1999a, Reny et al. 2002]. In addition, a constantly 
high or rising level of PCT during follow-up indicates adverse events and 
poor outcome, as reported in febrile patients [van Langevelde et al. 2000], 
in patients with CAP [Boussekey et al. 2005], in patients with severe acute 
pancreatitis [Rau et al. 2007], and in patients with septic shock [Clec’h et 
al. 2004]; whereas a decreasing level indicates higher probability of survival 
[Claeys et al. 2002]. 
High circulating levels of IL-6 are consistently associated with poor 
outcome in patients with fever [van Langevelde et al. 2000], bacterial 
infections [Norrby-Teglund et al. 1995], sepsis [Hack et al. 1989, Calandra et 
al. 1991, Doff erhoff  et al. 1992, Casey et al. 1993, Pinsky et al. 1993, Damas et 
al. 1997, Martins et al. 2003], and cardiogenic shock [Geppert et al. 2002]. On 
the basis of their results, Martins et al. [Martins et al. 2003] also concluded 
that levels of IL-6 are not infl uenced by administration of antimicrobial 
therapy. A study of patients with CAP showed high on-admission levels of 
IL-6 to be associated with mortality, with the highest among patients with 
CAP caused by pneumococcus [Ortqvist et al. 1995]. High circulating levels 
of IL-8 have predicted mortality in patients with sepsis [Damas et al. 1997]. 
In an ED setting, high circulating levels of IL-8 as well as APACHE II scores 
have predicted mortality of patients with SIRS better than did IL-6 or age 
[Lin et al. 2000]. In CAP, both IL-6 and IL-8 have been associated with 
severity of illness [Igonin et al. 2004]. Soluble IL-2R has not been studied 
with regard to its utility in predicting mortality in patients with infection, 
but high levels of sIL-2R have been reported to predict all-cause mortality 
in hospitalised elderly men [Rosenthal et al. 1997].
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High levels of phagocyte CD11b expression have been associated with 
organ failure in patients with sepsis [Takala et al. 1999a]. Glück et al. found 
that mCD14 failed to predict mortality of patients with sepsis, whereas a 
high level of sCD14 was related to 28-day survival in patients with a severe 
form of the disease [Gluck et al. 2001]. Other studies report that high sCD14 
levels may predict mortality in patients with sepsis [Landmann et al. 1995, 
Burgmann et al. 1996]. In patients with trauma, persistently low mCD14 
has been associated with secondary infections and death [Heinzelmann et 
al. 1996].
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7 AIMS OF THE STUDY
Th e overall purpose of this study was to investigate various markers of 
systemic infl ammation in patients with community-acquired infection, and 
their value in the diagnostics of infection and in prediction of mortality.
Th e specifi c aims were as follows:
1. To investigate whether the value of markers of systemic infl ammation 
(CRP, PCT, IL-6, IL-8, or sIL-2R) predict a positive blood culture 
result in acutely ill patients with a suspicion of community-acquired 
bloodstream infection (I) 
2. To investigate whether any single marker of systemic infl ammation 
(CRP, PCT, IL-6, IL-8, sIL-2R, or phagocyte CD11b) or a combination 
of markers can identify patients with a hidden infectious focus (II)
3. To evaluate whether on-admission-measured markers of systemic 
infl ammation (CRP, phagocyte CD11b, or monocyte CD14) can predict 
28-day mortality of patients with community-acquired infection (III)
4. To explore the interrelationship between monocyte CD14 and soluble 
CD14 and their combined predictive value for 28-day mortality in 
patients with community-acquired pneumonia or blood culture-positive 
sepsis or both (IV)
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8 MATERIAL AND METHODS
8.1 PATIENTS
A total of 1092 acutely ill patients (age 16 years or over) admitted during 
an 11-month period between September 1997 and August 1998 to the 
medical emergency department (ED) of the Meilahti Hospital, Helsinki 
University Central Hospital (HUCH), were evaluated. Th e trigger for 
enrolment was the clinician’s suspicion of infection and request for a blood 
culture. Laboratory assays were done in the Department of Bacteriology and 
Immunology, Haartman Institute, University of Helsinki; in the Departments 
of Clinical Chemistry and the laboratory of Women’s Hospital, HUCH; and 
in the laboratory of the Central Finland’s Central Hospital, Jyväskylä. Th e 
institutional review board of HUCH approved the study protocol.
 Th e medical history, clinical fi ndings, diagnosis of hospitalisation, and 
data on 28-day survival were collected retrospectively from the medical 
records and National Population Register Centre of Finland. On admission, 
clinical parameters collected (when available) were peak pulse rate, and 
nadir mean arterial pressure (MAP, mmHg), respiratory rate, and body 
temperature. Acute onset fever (I) was defi ned as a body temperature > 38°C, 
and acute abnormal body temperature (II) as body temperature > 38°C or 
< 36°C on admission or within 48 hours before admission.
Because the focus was on those patients with a suspicion of CAI and 
on the enhancing diagnostics of CAIs by means of markers of systemic 
infl ammation, exclusion criteria were developed accordingly. Fig. 2 shows the 
patients, exclusion criteria, and patient allocation to the studies. Patients with 
active malignancies were excluded due to the possible immune-infl ammatory 
changes accompanying malignant processes. All patients on any systemic 
immunosuppressive treatment other than prednisolone < 5 mg per day (or 
equivalent) were excluded, due to the possible eff ect on levels of infl ammation 
markers. Th e eff ect of other corticosteroids can be estimated with the 
equivalent dose of prednisone [Hardman and Limbird 2001]. Cytotoxic 
drugs can cause immunosuppression by interfering with DNA synthesis and 
thus killing cells that are dividing. Next, patients who had undergone surgery 
within the previous 6 weeks and patients hospitalised within the previous 14 
days were excluded, due to the possibility of nosocomial infection. Lastly, 
patients with insuffi  cient data on the hospitalisation period or 28-day survival 
or whose sample handling had failed were also excluded. 
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In Study I, recruitment and sample handling were tested in acutely ill 
patients. Th e analysis comprised 92 acutely ill patients who were allocated 
into 3 groups according to their clinical features on admission: Group I 
comprised 54 patients with infectious focus verifi ed on admission, Group II 
25 patients with acute onset fever without infectious focus on admission, and 
Group III, 13 patients with neither fever nor infectious focus. Groups II and 
III were further divided into 2 subgroups (A and B), to denote patients whose 
infectious focus was and was not verifi ed within the 3-day follow-up.
Study II included 138 patients with an abnormal body temperature: < 
36°C or > 38°C on admission or within 48 hours before hospital referral, but 
without infectious focus verifi ed on admission. According to the cumulative 
information during a follow-up lasting up to 3 days, of the 138, 26 had a 
verifi ed CAI  (infection group), 23 had a non-infectious cause of acute 
illness (control group), and 89 had neither an infectious focus nor any other 
reason verifi ed, but the presence of hidden infection could not be excluded 
(possible-infection group).
Study III included 327 patients with a verifi ed CAI with an infectious 
focus or positive blood culture on admission or within the 3-day follow-up 
aft er admission.  
Study IV included 142 patients who had, on admission or within the 
3-day follow-up, CAP (99 patients, 10 positive for blood culture) or positive 
blood culture without pneumonia (43).
Blood samples from healthy volunteers
Parallel to the patient series, healthy volunteers´ blood samples were collected 
from among laboratory research personnel. Th is group included 59 persons 
without clinical signs of infection, from whom 83 blood samples were drawn 
between January and August 1998 and processed in a similar manner as the 
patient samples. 
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21 765 patients admitted to Meilahti medical emergency department 
between September 1997 and August 1998
Clinician´s suspicion of an infection → 
request for a blood culture sample
1092 patients sampled for blood culture
Exclusions
Active malignancy 219
Hospitalised within the previous 14 days 67
Surgery within the previous 6 weeks 56
Systemic immunosuppressive treatment 172
other than prednisolone < 5 mg per day (or equivalent)
Missing data 29
Sample-handling failure 18
531 acutely ill patients with suspicion of community-acquired infection
Study I 





138 with abnormal 
body temperature 











culture in Studies 
II to IV
Figure 3. Patients, exclusion criteria, and allocation to Studies I to IV
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8.2 CLINICAL DIAGNOSIS OF THE INFECTIOUS FOCI
Th e infectious foci were defi ned as pneumonia, evidenced by respiratory 
symptoms associated with an acute infi ltration in the chest radiograph; 
urinary tract infection, evidenced by compatible fi ndings in urinalysis; 
central nervous system infection, evidenced by fi ndings in cerebrospinal 
fl uid; abscesses, evidenced by fi ndings in ultrasound examination or 
computerised tomography; sinusitis, evidenced by radiological fi ndings and 
purulent discharge in sinus puncture; malaria, evidenced by the presence of 
malarial plasmodia in the microscopic examination of the blood; spondylitis, 
evidenced by compatible fi ndings in radiographs; cholecystitis, cholangitis, or 
endocarditis, evidenced by compatible fi ndings in ultrasound examination; 
hepatitis A or nephropatia epidemica (a form of haemorrhagic fever caused 
by Puumala Hantavirus), evidenced by compatible fi ndings in serologic tests; 
and skin infection, tonsillitis, acute bronchitis, or acute-onset diarrhoea on 
the basis of the clinical picture. Lastly, an isolated positive blood culture 
was considered as an infectious focus, with the exception of blood cultures 
containing Staphylococcus epidermidis, Micrococcus, and Pseudomonas 
fl uorescens, which were considered contaminated if only one bottle revealed 
growth, and clinical fi ndings during follow-up were incompatible with sepsis; 
additionally, in the case of Staphylococcus epidermidis, if no indwelling 
vascular catheters were in use [Weinstein et al. 1983b].
8.3 BLOOD SAMPLING
Simultaneously with sampling for blood culture, an additional blood sample 
was collected into a pyrogen-free acid/citrate/dextrose anticoagulated 
tube (Venoject; Terumo Europe, Leuven, Belgium). In order to minimise 
phagocyte activation ex vivo, each tube was immediately pressed into thawing 
ice (0°C) and kept cooled until cell labelling. Aft er the extraction of whole 
blood aliquots for the cell labelling, plasma was separated by centrifugation 
at 4°C and stored in aliquots at -70°C until use. Repeated freeze-thaw cycles 
were avoided as far as possible. 
8.4 DETERMINATION OF CELLULAR MARKERS CD11b 
AND CD14
8.4.1 Cell labelling
Monoclonal antibodies were as follows: CD11b- phytoerythrin PE (mouse 
anti-CD11b IgG1, clone 2LPM19c, Dako A/S, Glostrup, Denmark), and 
CD14-fl uorescein-isothiocyanate (FITC) (mouse anti-CD14 IgG2b, clone 
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MφP9, Becton Dickinson, San Jose, CA, USA). Blood samples were processed 
for fl ow cytometry daily. Preliminary experiments verifi ed that staining 
properties of the cells were virtually unaff ected by 24-h storage of the 
blood samples at 0°C (data not shown). Of the whole blood, 25 μl aliquots 
were double-labelled by the addition of saturating amounts of the mAbs 
on the basis of leukocyte count. Cells were washed by the addition of 1:10 
diluted ice-cold FACS lysing solution (Becton Dickinson) and collected by 
centrifugation at 4°C to lyse any remaining red cells. Th is procedure was 
repeated with the FACS lysing solution at room temperature. Th e pellets were 
resuspended in 400 μl of ice-cold saline supplemented with formaldehyde 
(fi nal concentration 0.5%), and the samples were kept at 0°C until analysis 
by fl ow cytometer. Next, 50 μl of microbeads (Quantum Simply Cellular®, 
QSC, Flow Cytometry Standards Corporation, San Juan, PR, USA) were 
stained and processed in a similar manner. Th e QSC preparation comprises 
a mixture of four highly uniform microbead populations of the same size 
which have varying capacities to bind mouse monoclonal IgG antibodies, 
plus a blank population [Serke et al. 1998].
8.4.2 Flow cytometry
A FACSort fl ow cytometer (Becton Dickinson) and CellQuest soft ware were 
used for acquisition and analysis of the data. A data set of 5 x 103 neutrophils 
identifi ed on the basis of their light-scattering properties was acquired. In 
order to determine CD11b fl uorescence of these neutrophils, a histogram 
of red fl uorescence was produced, and the arbitrary units (channel number) 
were transformed into antibody-binding capacity (ABC) units by analysis of 
similarly stained QSC microbeads. A regression curve of channel number 
against ABC was constructed by use of Quickal, the calibration soft ware 
provided with each lot of QSC microbeads. A data set of 103 CD14-positive 
events with light-scattering properties compatible with those of monocytes 
was acquired, and an analysis of CD11b fl uorescence of these cells was 
conducted as above. In addition, to determine the CD14 fl uorescence as 
ABC units, a histogram of green fl uorescence was analysed against similarly 
stained QSC microbeads. 
Th e median level of mCD14 in samples from healthy volunteers was 
105 536 ABC (interquartile range (IQR) 91 087, 117 965), of neutrophil 
CD11b 24 170 ABC (17 748, 26 295), and of monocyte CD11b 27 411 ABC 
(21 919, 31 087).
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8.5 DETERMINATION OF SOLUBLE MEDIATORS
8.5.1 Interleukin-6
IL-6 was measured by a chemiluminescent immunoassay system (Immulite®, 
Diagnostic Products Corporation, Los Angeles, CA, USA) with a detection 
limit of 5 ng/l.
8.5.2 Interleukin-8
IL-8 was measured by a chemiluminescent immunoassay system (Immulite®, 
Diagnostic Products Corporation) with a detection limit of 5 ng/l (I) and 
Quantikine® Human IL-8 Immunoassay (R&D Systems Inc., Minneapolis, 
MN, USA) with a minimum detectable dose of 3.5 ng/l (II).
8.5.3 C-reactive protein
Serum concentrations of CRP were determined by an immunoturbidimetric 
assay with a detection limit of 5 mg/l. 
8.5.4 Procalcitonin
Plasma samples for PCT were analysed by an immunoluminometric assay 
(LUMItest PCT®, B.R.A.H.M.S. Diagnostica, Berlin, Germany), with a 
detection limit of 0.01 μg/l and a functional assay sensitivity of 0.30 μg/l.
8.5.5 Soluble receptors
Soluble IL-2R (I) was measured by a chemiluminescent immunoassay system 
(Immulite®, Diagnostic Products Corporation) with a detection limit of 10 
kU/l. Soluble CD14 and sIL-2rα (II) were measured by Quantikine® Human 
sCD14 and IL-2rα Immunoassay (R&D Systems Inc.) with a minimum 
detectable dose of 125 pg/ml and 10 ng/l, respectively. Diagnostic Products 
Corporation was unable to provide any tool to compare Immulite sIL-2R 
measurements to R&D Systems Quantikine® sIL-2Rα measurements.
8.6 DATA ANALYSIS 
Th e results are expressed as mean or median with SD or range and 95% 
confi dence intervals (95% CI). Variables with non-normal or ordinal 
values are expressed by median and interquartile range (IQR). Measures 
with a discrete distribution are expressed as counts (%). Variables with 
normal distribution are expressed by mean and standard deviation (SD). 
Th e normality of variables was evaluated by Shapiro-Wilk statistics (III). 
Comparisons between multiple groups were performed with the Kruskal–
Wallis test (I, II) and the permutation test (I). Comparison between two 
groups was done by t-test (II, III), Mann-Whitney U-test (III), or permutation 
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test with a Monte Carlo p-value (III, IV). In addition, measures with a 
discrete distribution were analysed by χ2 (II, III) or Fisher’s exact test (III). 
Linearity in infl ammation markers between groups was analysed by rank-
based linearity contrast with bootstrap-based multiplicity-adjusted p-values 
[Westfall and Young 1993].
Correlations were estimated by Spearman’s correlation coeffi  cient method 
(IV). Th e predictive value of measured markers was evaluated with the 
area under the receiver operating characteristic curve (AUCROC) and bias-
corrected bootstrap CI (I). In Study II, the infl ammation marker level with 
the highest accuracy (sum of sensitivity and specifi city) was determined 
from a receiver operating characteristic curve, the respective area under the 
curve (AUC) was calculated, and 95% CI was obtained by bias-corrected 
bootstrapping (50 000 replications). Th e cut-off  level was chosen according 
to the combination of best possible sensitivity and specifi city.
Survival time was analysed by univariate and multivariate (forward 
stepwise procedure) proportional hazard regression models, called Cox’s 
regression models (III). Th e Kaplan-Meier curve illustrated information 
on the cumulative proportions of survival. Diff erence between groups was 
tested by Log-rank test (Monte Carlo p-value) (III) or by a permutation type 





A total of 531 patients were included in the fi nal analysis of Studies I to IV 
(Table 2). 
Table 2. Characteristics of all patients
Variable
Study
I II III IV
Number of patients 92 138 327 142
Age, years, mean (range) 52 (18-88) 50 (16-93) 55 (16-94) 60 (16-94)
Sex, male/female, n 44 / 48 79 / 59 175 / 152 83 / 59
Length of stay, mean (range) 9 (1-40) 8 (1-46) 10 (1-69) 13 (1-69)
Mortality in 28 days, n (%) 3 (3.3) 4 (2.9) 11 (3.4) 10 (7.0)
Positive blood culture, n (%) 13 (14.1) 14 (10.1) 54 (16.5) 53 (37.3)
In Study I, the analysis comprised 92 acutely ill patients allocated into 3 
groups according to their clinical features on admission: Group I comprised 
54 patients with infectious focus, Group II, 25 patients with acute onset of 
fever without infectious focus on admission, and Group III, 13 patients with 
neither fever nor infectious focus on admission. As a preliminary setting, 
Groups II and III were to be further divided into 2 subgroups (A and B), to 
denote patients in whom infectious focus was verifi ed, and was not, within a 
3-day follow-up. However, in Group III no infectious focus emerged during 
the 3-day follow-up. So the fi nal subgroup analysis consisted of the infection 
group and the combined possible-infection and control group (Groups IIA 
and IIB, respectively, in Study I). For diagnoses see Table 3. A total of 13 
patients, 10 in Group I and 3 in Group II, had positive blood cultures (see 
Table 4 for species and numbers of cases). In 21 patients, antimicrobial 
therapy had been started before sampling for blood culture, and of these 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Study II included 138 patients presenting with abnormal body temperature: 
< 36°C or > 38°C on admission or within 48 hours before hospital referral, 
but without infectious focus verifi ed on admission. Of these 138, 26 patients 
had a CAI with verifi ed focus (infection group) within a follow-up of up 
to 3 days (Table 5). Th eir diagnoses were: pneumonia (n=6), abscess (3), 
skin infection (2), nephropatia epidemica (2), and a single case each of 
urinary tract infection, endocarditis, cholangitis, and hepatitis A. In 23 
patients, a non-infectious acute illness was found in concert with no clinical 
suspicion of infection during follow-up (control group). Th e diagnoses in 
this group were congestive heart failure (n=5), epileptic convulsion (4), 
thromboembolic disease (3), drug intoxication (2), reactive arthritis (2), 
and a single case each of diabetes, gout, multiple sclerosis, nitrofurantoin-
induced lung disease, pleural pain, pneumothorax, and suspected sarcoidosis. 
Finally, 89 patients showed neither infectious focus nor other cause, yet the 
presence of hidden infection could not be excluded (possible-infection 
group). Th ese patients were categorised into three subgroups: patients with 
fever or hypothermia but without other clinical symptoms (n=40), with fever 
with various respiratory symptoms (35), and with fever with miscellaneous 
symptoms (14). In 22 patients (5 in the infection group, 14 in the possible 
infection group, and 3 in the control group) antimicrobial therapy had been 
started before sampling for blood culture; in 2 of these patients the blood 































































































































































































































































































   


























   

























   
















































































































Study III comprised 327 acutely ill patients with a community-acquired 
infection verifi ed on admission or during a follow-up of up to 3 days 
(Table 6). Th e 28-day mortality rate was low, 3.4% (11 patients). Th e most 
frequent types of infection were pneumonia (n=195), skin infection (81), 
and urinary tract infection (67). A total of 54 patients (16.5%) had blood 
cultures positive for Escherichia coli (n=15), Streptococcus pneumoniae 
(9), Staphylococcus aureus (5), β-haemolytic group G Streptococcus (4), 
Staphylococcus epidermidis (3), Klebsiella oxytoca (2), Streptococcus pyogenes 
(2), viridans group Streptococcus (4), and one each for Enterobacter cloacae, 
Enterococcus faecalis, Pseudomonas aeruginosa, Salmonella paratyphi B, 
Serratia liquefacien, Streptococcus agalactiae (B), Streptococcus intermedius, 
for both Escherichia coli and viridans group Streptococcus, and for both 
Staphylococcus epidermidis and viridans group Streptococcus. Nine patients 
had sepsis with positive blood culture but with no clinically detectable 
sign of infectious focus. Of the 11 patients who died, 7 had pneumonia 
and 4 a positive blood culture (Table 7). A total of 56 patients had received 
antimicrobial therapy before sampling for blood culture, and of these 
patients, 7 had a positive blood culture. 
Emerging from the patient material in Study III, in Study IV the focus 
was narrowed to acutely ill patients with the most common and severe CAIs, 
namely to 142 patients who had either pneumonia (99 patients, 10 positive 
for blood culture) or positive blood culture without pneumonia (43). 
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   Male, n (%) 168 (53) 7 (64) 0.49
   Age, years, mean (SD) 55 (21) 70 (17) 0.018
Clinical data:
   Infectious focus on admission, n (%) 290 (92) 9 (82) 0.24
   Body temperature 0.41
      36-38°C, n (%) 136 (44) 4 (40)
      > 38°C, n (%) 168 (54) 5 (50)
      < 36°C, n (%) 9 (3) 1(10)
   MAP, mmHg, mean (SD) 88 (16) 74 (22) 0.010
   Heart rate, beats per minute, mean (SD) 93 (18) 113 (30) 0.001
Laboratory data:
   WBC count, x 109/l, median (IQR) 10.9 (7.3, 14.5) 11.8 (7.9, 19.8) 0.43
   WBC count 0.25
      normal, 4–12 x109/l, n (%) 177 (57) 5 (46)
      high, > 12 x109/l, n (%) 121 (39) 5 (46)
      low, < 4 x109/l, n (%) 13 (4) 1 (9)
   Serum CRP, mg/l, median (IQR) 82 (32, 158) 113 (65, 315) 0.028
   Platelet count, x109/l, median (IQR) 219 (174, 265) 141 (83, 210) 0.048
   CD11b
      PMN, x103 ABC, median (IQR) 32.8 (24.0, 44.9) 36.9 (26.6, 55.0) 0.16
      MO, x103 ABC, median (IQR) 38.2 (28.7, 52.2) 43.8 (32.9, 58.0) 0.76
   mCD14, x103 ABC, median (IQR) 84.9 (67.0, 108.5) 61.8 (40.6, 76.5) 0.022
























































































































































































































































































































































9.2 ENHANCING DIAGNOSTICS OF INFECTION
In Studies I and II various laboratory markers of systemic infl ammation 
were evaluated in order to improve the prediction of positive blood culture 
and diagnostics of hidden community-acquired infection on admission. 
Cut-off  levels for markers of infl ammation were developed according to 
the presence or absence of infectious focus (II), or a positive blood culture 
(I) (Table 8).




Marker of infl ammation I II
Serum CRP, mg/l ≥ 125 ≥ 57
Plasma PCT, μg/l ≥ 0.40 ≥ 0.30
Plasma IL-6, ng/l ≥ 257 ≥ 104
Plasma IL-8, ng/l ≥ 19 ≥ 11.8
CD11b
   MO, x103 ABC N/A ≥ 38.5
   PMN, x103 ABC N/A ≥ 29.6
Plasma sIL-2R, kU/l ≥ 2 400 N/A
Plasma sIL-2Rα, μg/l N/A ≥ 1.63
CRP, C-reactive protein; PCT, procalcitonin; IL, interleukin; CD, cluster of 
diff erentiation; MO, monocyte; PMN, neutrophil; ABC, antibody-binding capacity; 
N/A, not available; sIL-2R, soluble interleukin 2 receptor
9.2.1 Bloodstream infection (I)
In Study I, a total of 13 patients had positive blood cultures, 10 among 
patients who presented with an infectious focus (Group I) and 3 among 
patients with fever in the absence of an infectious focus on admission (Group 
II). Table 4 shows the levels of CRP, PCT, and cytokines of the 13 patients 
with positive blood cultures on admission.
According to clinical fi ndings and the number of positive blood cultures, 
the presence of an infectious focus with fever had a sensitivity of 100% 
(95% CI, 75 to 100), a specifi city of 16% (95%CI, 9 to 26), a PPV of 16% 
(95%CI, 9 to 26), and a NPV of 100% (95%CI, 75 to 100). On the other 
hand, evaluation of the diagnostic accuracy of the laboratory markers of 
infl ammation measured (CRP, PCT, IL-6, IL-8, and sIL-2R) according to 
their respective cut-off  levels, showed their range of PPVs to be 33 to 44% 
























































































































































































































































































































































































9.2.2 Hidden infection (I, II)
In Study I, in addition to predicting positive blood culture, the patients 
in Groups II and III were further evaluated according to the results of the 
3-day follow-up. In eight Group II patients, an infection was subsequently 
verifi ed, but in Group III no patient proved to have an infection as the cause 
of fever. Th us, in the subgroup analysis of Group II, the levels of IL-6 and 
sIL-2R were signifi cantly higher on admission in patients with fever due 
to infectious focus (infection group IIA) than were the respective levels in 
patients with fever only (combined possible-infection and control group IIB) 
(p = 0.005 and p = 0.046, respectively; Table 10). Between these groups, CRP, 
PCT, and IL-8 did not diff er signifi cantly. Th e three patients with a positive 
blood culture in the infection group (IIA) had the highest CRP levels (see 
also Figure 1A in Study I).  
Th e small size of Group II in Study I did not allow any further statistical 
analysis of the diagnostic accuracy of the infl ammation markers. Th e 
promising diff erences between those subgroups prompted us to conduct a 
larger study including acutely ill patients with abnormal body temperature 
but without any infectious focus on admission. In Study II, the combined 
possible-infection and control group was further divided into a possible-
infection group and a control group. Beside the soluble markers of 
infl ammation measured in Study I (CRP, PCT, IL-6, IL-8, and sIL-2R), Study 
II introduced a cell-bound marker of systemic infl ammation: phagocyte 
CD11b expression level. All the on-admission levels of these infl ammation 
markers diff ered signifi cantly between the patient groups (Table 10). Of 
the standard laboratory variables, the WBC count fell within the reference 
limits in half of the patients with a hidden infection, and > 12 x109/l in 5 
(21.7%) of the patients in the control group (Table 5). In further analysis, 
IL-6 and PCT had the highest LR+ for infection (7.52 and 6.44) (Figure 3; see 
also Table 4 in Study II), but at the same time, two patients in the infection 
group, despite a clear infectious focus, presented with IL-6 and PCT levels 
below their respective cut-off  levels (for cut-off  levels see Table 8). On the 
other hand, all the patients in the infection group were detected with the 
combination of neutrophil CD11b, IL-8, and CRP. When this combination 
was applied to the possible-infection group, all markers fell below their 
respective cut-off  levels in 13.5% of the patients (for post hoc clinical analysis 


























































































































































































































































































































































































































































































































































































































































































































































Values are expressed with 95% CI. In parentheses, the respective cut-off  levels; see 
Table 8
For abbreviations see Table 8
Sensitivity                      False Positive Probability
















Figure 3. Th e sensitivity and false-positive probability of on-admission-measured 
infl ammation markers in diagnosing community-acquired hidden infection in patients 



















































































































































































































































































































































































9.3 PREDICTION OF 28-DAY MORTALITY (III, IV)
In Study III, the on-admission expression levels of phagocyte CD11b and 
mCD14 along with demographic, clinical, and basic laboratory variables 
were evaluated in predicting 28-day mortality of acutely ill patients with 
CAI. Compared to survivors, non-survivors were signifi cantly older, had 
a lower mCD14 expression level, lower MAP, higher heart rate, higher 
CRP level, and lower platelet count. Th e groups did not diff er signifi cantly 
in terms of gender, body temperature, WBC count, or phagocyte CD11b 
expression level. 
Further statistical analyses revealed that in univariate analysis, age, lowest 
tertile of MAP, highest tertile of heart rate, and lowest tertile of mCD14 
expression level each had a signifi cant predictive value (Table 12). Secondly, 
in multivariate analysis, age and lowest tertile of mCD114 expression level 
remained predictive for 28-day mortality (Figure 4).
Aft er the result concerning the predictive value of mCD14, a question 
arose as to the value of the simultaneous measurement of sCD14. In Study 
IV, the focus was narrowed to the most common and severe CAIs, namely 
pneumonia and sepsis, and evaluation of the combined value of mCD14 and 
sCD14 followed. As a result, no signifi cant correlation appeared between 
mCD14 and sCD14 (see also Figure 2 in Study III). CRP was related to 
sCD14 (r = 0.29, 95% CI 0.13 to 0.45), but not to mCD14 (r = -0.10, 95% 
CI -0.27 to 0.09). Th e 28-day survival rate was 83.4% (95% CI 70.3 to 94.2). 
Th e non-survivors had signifi cantly lower mCD14 expression levels than 
did survivors, whereas sCD14 levels did not diff er between groups. Patients 
in the lowest tertile of mCD14 were 9.79 times (95% CI 1.31 to > 50, p = 
0.006) more likely to die than were patients in the combined middle and 
highest tertiles. Survival rates in the highest and in the combined middle 
and lowest tertiles of sCD14 levels were comparable. Aft er stratifi cation by 
sCD14, patients in the lowest tertile of mCD14 were 14.4 times (95% CI 














































































































































































































































































































































































































































































































































































Figure 4. Kaplan-Meier curves for the lowest and the combined middle and highest 
tertiles of mCD14 expression 
• denotes estimates of 28-day survival rate. 95% CI obtained by bias-corrected and 
accelerated bootstrapping (5000 replications)
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10 DISCUSSION
Th e present study is based on an analysis of 531 patients with pure 
community-acquired infection (CAI). Th e markers of systemic infl ammation 
in emergency department (ED) settings have frequently been studied in series 
including patients with nosocomial infections as well as in patients with CAI 
[Terregino et al. 2000, Guven et al. 2002, Hausfater et al. 2002, Adams 2005, 
Huang et al. 2005, Wyllie et al. 2005]. Data in some recent reports have, 
however, supported the more detailed classifi cation of patients´ illnesses 
as community-acquired, health-care-associated or nosocomial [Siegman-
Igra et al. 2002]. In patients with CAI, the microbiology and outcome diff er 
from those in patients with health-care-associated and nosocomial infection 
[Friedman et al. 2002, Chi et al. 2004, Kollef et al. 2005, Liao et al. 2005]. 
Th is diff erence may also involve the markers of systemic infl ammation. 
Th e homogeneity of the triggering external and internal environment is the 
strength and unique feature of this study. 
10.1 ENHANCING DIAGNOSTICS OF INFECTION
Th e diagnostics of infection on admission still rely mostly on indirect 
methods (radiology, urinalysis, other semi-quantitative quick tests of soluble 
markers) and the patient’s clinical appearance, since the results of various 
cultures are available at the earliest on the following day. Similarities in 
their clinical presentation between viral and bacterial infections result in 
an extensive use of antimicrobial therapy. Besides the general signs of acute 
illness (fever, fatigue, loss of appetite) together with the characteristic clinical 
signs of local bacterial infection, other indicators of bacterial infection 
include various markers of systemic infl ammation. 
When infection is suspected, leukocyte count is routinely checked 
to discover any abnormality. Th e increase in proportion of immature 
neutrophils, known as band forms, might be more specifi c for infection 
than is total count of leukocytes [Wile et al. 2001]. Th e band proportion is 
determined manually [van der Meer et al. 2006] and is oft en unavailable, for 
example, in Helsinki, outside offi  ce hours. Whether the band proportion gives 
additional information concerning the diagnosis of infection is controversial 
[Shapiro and Greenfi eld 1987]. 
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10.1.1 Bloodstream infection (I)
A positive blood culture is not always clinically signifi cant, and also 
false-negative results represent a signifi cant clinical problem. Although 
patients with a positive blood culture, i.e., bacteraemia, represent quite 
a heterogeneous population, a positive blood culture is a practical and 
clear endpoint and has been the gold standard for infection diagnostics 
research. Th erefore, for screening acutely ill patients, a marker predicting 
with sensitivity and accuracy microbial growth in blood culture would prove 
extremely useful. 
In Study I, each of the 13 patients with bloodstream infection (BSI) had a 
detectable infectious focus, or if no obvious focus could be verifi ed, at least 
had fever. Th us, the absence of fever or of an infectious focus had a high 
negative predictive value (NPV, 100%), but a very low positive predictive 
value (PPV, 16%) for BSI, in accordance with previous reports [Groeneveld 
et al. 2001]. Like the clinical markers, the present cut-off  levels of CRP, 
PCT, IL-6, IL-8, and sIL-2R had high NPVs (92 to 98%) and low PPVs 
(33 to 44%), indicating that the markers of systemic infl ammation did not 
improve the sensitivity at which we have detected patients with BSI, and 
this is also supported by other studies [Moscovitz et al. 1994, Engel et al. 
1999, Persson et al. 2004].  
Our set of laboratory markers for the detection of BSI was developed to 
measure both early (PCT, IL-6, IL-8) and advanced (CRP, sIL-2R) immune 
infl ammatory reactions [Takala et al. 2002b]. In Finland, the most widely 
used marker of infection and BSI is CRP. Its present cut-off  level of 125 mg/l 
to rule out BSI (Study I) showed power equal to that of newer markers in an 
ED setting. Numerous other illnesses aff ect the level of CRP, oft en increasing 
it, CRP not being a specifi c marker for BSI [Adams 2005]. When examined 
at an early stage of BSI, CRP is not associated with patient outcome [Takala 
et al. 1999a]. 
PCT has been studied extensively in patients with hospital-acquired 
infection but studied less as a marker of community-acquired BSI. PCT 
is useful in the early phase of bacteraemia [Rintala et al. 2001]. In a study 
of community-acquired bacteraemia, the optimal cut-off  level of 0.4 μg/l 
for PCT was associated with a NPV of 98.8% [Chirouze et al. 2002]. In the 
present study, the respective values were strikingly similar, 0.4 μg/l and 98%, 
but the PPVs in both studies were low: 25% and 33%, which strongly limits 
the use of PCT in clinical medicine. Besides PCT, when compared to CRP, 
the use of IL-6 [Moscovitz et al. 1994] or IL-8 [Lin et al. 2000] provided 
little impact in predicting BSI. In sum, these markers performed better in 
ruling out than in ruling in the possibility of BSI.
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10.1.2 Hidden infection (I, II)
In patients presenting with an infectious focus, the initial working diagnosis 
and the initiation of appropriate antimicrobial therapy are easy. In contrast, the 
diagnostics is diffi  cult in patients presenting with only fever or hypothermia 
but without an evident infectious focus on admission. Th e clinical follow-up 
and further investigation of these patients may fi nally verify or exclude the 
infection as the underlying cause of acute illness. Study I revealed that on-
admission levels of IL-6 and sIL-2R were higher, and those of IL-8 and CRP 
tended to be higher in patients with infection than in those without.   
In Study II these markers of systemic infl ammation were used to screen 
a larger population of patients without infectious focus on admission. 
Of the single markers, IL-6 and PCT had the highest positive likelihood 
ratio (LR+) for detecting CAI, a fi nding supported by other studies that 
include patients with infection [Terregino et al. 2000, Chan et al. 2004, 
Uzzan et al. 2006]. However, in Study II, IL-6 and PCT failed to detect 2 
patients with clinically signifi cant pneumonia. Th at all the patients with 
infection could be detected with a combination of markers including CRP, 
CD11b, and IL-8 supports the idea that infl ammation is a dynamic process 
involving sequential activation of the innate immune system [Waage et 
al. 1989, Cooney and Yumet 2002]. Identifying all patients with systemic 
infl ammation therefore requires combined markers covering all the stages 
of systemic infl ammation. An increase in CD11b expression requiring no 
time-consuming de novo protein synthesis [Calafat et al. 1993] is an early 
marker of systemic infl ammation [Rinder et al. 1992]. Sequential generation 
of cytokines also occurs within hours in response to an insult [Waage et al. 
1989, Matsukawa and Yoshinaga 1998], and increased cytokine levels co-
occur with onset of fever. CRP levels peak later, 24 to 48 hours aft er onset 
of fever [Anonymous 1988, Rintala et al. 2001]. IL-8 guides neutrophil 
accumulation into tissues [Van Zee et al. 1992] and therefore may indicate 
a hidden tissue infection. Neutrophil CD11b, a sensitive marker of systemic 
infl ammation [Takala et al. 2002a] but nonspecifi c for infection [Takala et al. 
1999b], correlates positively with circulating IL-8 levels, and both markers 
facilitate the diagnosis of sepsis in neonates [Nupponen et al. 2001]. CD11b 
expression levels may, however, remain normal even in patients with blood 
culture-positive sepsis [Kuuliala et al. 2004]. Th e other markers evaluated in 
Study II  all serve as markers of systemic infl ammation: PCT [Guven et al. 
2002, Hausfater et al. 2002, Chan et al. 2004], IL-6 [Moscovitz et al. 1994, 
Ortqvist et al. 1995, Antunes et al. 2002], and sIL-2R [Kylanpaa-Back et al. 
2001b], a fact also demonstrated in Study II. 
Clinical studies of infl ammatory markers have included patients with 
an evident infectious focus and excluded patients with a possible infection 
[Groeneveld et al. 2001, Raaphorst et al. 2001, Chan et al. 2004, Nuutila et 
al. 2006]. Th e latter group is important because it comprises those patients 
not necessarily benefi ting from antimicrobial therapy. Study II included 
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a post hoc clinical analysis of the possible-infection group. Th e possible-
infection group proved very large, 89 (64.5%) of the 138 patients. Of these 
89, 12 (13.5%) displayed the combined markers below the marker cut-off  
levels, and 9 of them received empiric antimicrobial therapy. Obviously, in 
these patients without immunosuppression or any other similar predisposing 
factor, antimicrobial therapy could have been withheld or discontinued 
safely. On the other hand, in 12 patients (13.5%), the combined markers 
were all above their respective cut-off  levels, and all these patients were 
appropriately treated with antimicrobial drugs. Among the other 65 patients 
(a large majority of the possible-infection group) 1 or 2 of the markers 
exceeded the cut-off  level(s); thus, in these patients the combined markers 
did not add to clinical decision-making.
10.2 PREDICTION OF 28-DAY MORTALITY (III, IV)
In the present study, 28-day mortality of those patients with a CAI was low 
(3.4%), and the number of non-survivors small (n=11), but in accordance 
with earlier data [Esel et al. 2003, Shapiro et al. 2006]. Th us, interpretation 
of outcome data must be limited to patients with CAI and be confi rmed 
in larger populations. Our patients with CAI represented a heterogeneous 
population, including subgroups already with various prognostic factors 
on admission, for example, an elderly patient with a urinary tract infection 
(UTI) vs. a community-acquired pneumonia (CAP), infl uencing 28-day 
mortality. A laboratory marker for predicting the prognosis of CAI would 
still prove useful, since the status of any patient with any CAI may worsen 
quickly and may lead to shock and even to death. Such a marker might aid 
in intensifying treatment early enough and in better targeting the expensive 
new immunomodulative treatments. 
Study III showed that age and low monocyte membrane CD14 (mCD14) 
expression level, as determined on admission to hospital, were associated 
with poor prognosis among CAI patients. In patients with serious infections, 
age is associated with poor prognosis [Ruiz et al. 1999, van Langevelde et 
al. 2000, van de Beek et al. 2004, Roson et al. 2004]. To our knowledge, 
mCD14 expression level as a prognostic factor has not been studied in 
patients with CAI. In hospitalised patients, on-admission levels of mCD14 
in those with sepsis were lower [Ertel et al. 1993, Lin et al. 1993, Gluck et al. 
2001], and low levels correlated with severity of infection [de Werra et al. 
2001], whereas persistently low levels correlated with fatal outcome [Gluck 
et al. 2001]. In patients with severe trauma [Heinzelmann et al. 1996] or 
severe acute pancreatitis [Kylanpaa-Back et al. 2001a]–both representing 
systemic infl ammation in the absence of infection–on-admission mCD14 
expression level was not associated with clinical outcome. Th ese fi ndings 
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thus suggest that low mCD14 expression on admission may indeed predict 
mortality in pure CAI.
An important question is whether the clinical outcome of those 
patients with low mCD14 expression might be improved. According to the 
current concept, systemic infl ammation contributes to the development of 
dysfunction of vital organs which, in patients with sepsis, is the major cause 
of mortality (reviewed in Takala et al. [2002b]). At an early, proinfl ammatory 
stage of systemic infl ammation, characterised by systemic release of TNF 
and other proinfl ammatory cytokines, interfering with the cytokines 
might prove benefi cial. Th is early stage is, however, rapidly followed by 
an anti-infl ammatory reaction which leads to immune suppression or 
even anergy characterised by depressed monocyte HLA-DR expression 
and TNF production capacity [Tschaikowsky et al. 2002, Mentula et al. 
2004]. At this stage, depression of TNF production may be detrimental 
and immune stimulation benefi cial [Docke et al. 1997]. Stimulated TNF 
production by monocytes expressing low mCD14 is reported to be decreased 
[de Werra et al. 2001], and this may indirectly suggest that low mCD14 
refl ects defective monocyte function. In vitro bacterial products have led 
lead to increased CD14 expression and survival of monocytes [Landmann 
et al. 1996], whereas anti-infl ammatory cytokines [de Waal Malefyt et al. 
1993] and also glucocorticoids [Sumegi et al. 2005] usually down-regulate 
CD14 expression. In vitro down-regulation of mCD14 expression has been 
suffi  cient to trigger monocyte apoptosis [Heidenreich et al. 1997]. Th us, our 
patients with low mCD14 levels may be candidates for immune-stimulatory 
therapy to alter the course of their systemic infl ammation, but always on the 
basis of evaluation of immune–infl ammatory status in a single patient. 
In Study IV, low mCD14 levels, but not the circulating soluble CD14 
(sCD14) levels, predicted 28-day mortality of the patients with CAP or 
community-acquired blood culture-positive sepsis or both. Our fi ndings 
diff er from the results of a study by Glück et al. [2001] indicating no 
correlation between mCD14 levels and 28-day mortality in patients with 
sepsis. In addition, Glück et al. [2001] found that a high sCD14 level was 
associated with survival by day 28. Study IV indicated that sCD14 levels did 
not correlate with clinical outcome. Th ese discrepancies may be explained 
by diff erences in inclusion of patients, in sample handling, and in fl ow 
cytometric analysis.
In addition, in Study IV, mCD14 levels did not correlate with sCD14 
levels. Th is is understandable in the context of the fi ndings that besides 
being shed from monocytes [Bazil and Strominger 1991], sCD14 is expressed 
and secreted by human hepatocytes [Su et al. 1999]. Indeed, evidence has 
accumulated to show that sCD14 serves as an acute phase reactant in 
parallel with CRP, a classical acute phase protein [Bas et al. 2004]. Th is 
idea is supported by our fi nding that the patients’ sCD14 levels correlated 
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with their CRP levels. In addition, sCD14 may enhance mCD14-positive 
cells´ response to bacterial structures [Dziarski et al. 2000], and contribute 
to elimination and detoxifi cation of bacterial endotoxins [Yu et al. 1997]. 
Furthermore, despite the lack of correlation between sCD14 and mCD14, 
high sCD14 levels appeared to strengthen the ability of mCD14 to predict 
28-day mortality.  
Of the other markers of infl ammation, in patients with sepsis, an increased 
level of phagocyte CD11b/CD18 expression at an early stage of the disease 
has been associated with the development of organ failure and also has 
been a suitable early marker for screening systemic infl ammation in acutely 
ill patients [Takala et al. 2002b]. In patients with septic shock, neutrophil 
CD11b/CD18 expression level has been correlated with severity of disease 
[Chishti et al. 2004]. However, in the present study, phagocyte CD11b/CD18 
expression level was not associated with mortality. Th is may be due to the 
milder nature of CAI when compared to the conditions suff ered by ICU 
patients [Takala et al. 1999a]. Th e diff erences between these studies may also 
lie in their diff ering end-points (organ failure vs. mortality). CRP, an acute 
phase protein, is widely acknowledged as an infection marker, but without 
any prognostic value at the early stage of disease [Smith et al. 1995, Takala et 
al. 1999a]. Th e present study, therefore, although being signifi cantly higher 
in non-survivors than in survivors, showed that on-admission CRP levels 
did not predict poor outcome.
In sum, the results suggest that mCD14 expression could serve as a 
prognostic marker in patients with CAI, but this fi nding should be verifi ed 
in a larger population with a greater number of non-survivors. 
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11 CONCLUSIONS
1. Markers of systemic infl ammation (CRP, PCT, IL-6, IL-8, or sIL-2R) were 
unable to predict community-acquired BSI (I) 
2. In patients presenting with abnormal body temperature, all the markers 
of systemic infl ammation (CRP, PCT, IL-6, IL-8, sIL-2R, or phagocyte 
CD11b) were signifi cantly higher in patients with a hidden CAI than in 
patients without such infection. IL-6 and PCT had the highest LR+ for 
diagnosing infection, but they detected 24 of 26 (92.3%) of the patients 
with infection. A combination of CD11b, CRP, and IL-8 detected all 
patients with infection. Evaluation of patients with a possible infection 
requires a combination of infl ammatory markers (II)
3. In patients with CAI, advanced age and low on-admission mCD14 
expression level were associated with 28-day mortality (III)
4. In patients with severe CAI, high levels of sCD14 alone were not predictive 
of 28-day mortality. However, a high sCD14 level in combination with a 
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